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CHAPTER I INTRODUCTION
Gliomas
Gliomas are the most common primary brain tumor in adults. Gliomas are
tumors derived from glial cells or neural progenitor cells (Wen and Kesari, 2008)
and include ependymomas (< 10% of all gliomas), oligodendrogliomas (10 –
30%), and astrocytomas (60 – 70%) (Lefranc et al., 2005). Gliomas are classified
by the World Health Organization as Grades I – IV. Grade I is relatively rare,
indicated by low proliferative potential and the possibility of cure by surgical
resection alone (Louis et al., 2007). Grade II gliomas are characterized by
infiltration into the normal brain and low proliferative index. These tumors include
diffuse astrocytomas, oligodendrogliomas, and oligoastrocytoma, which often
recur and progress to higher grade tumors (Louis et al., 2007).

Anaplastic

astrocytoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma are
classified as Grade III gliomas and are considered malignant. They are
characterized by increased cellular density and increased mitotic activity with
abnormal nuclei (Louis et al., 2007; Wen and Kesari, 2008). Glioblastoma
Multiforme (GBM) is considered a Grade IV glioma and can arise from the
transformation of lower grade gliomas or can develop de novo (Lefranc et al.,
2005; Wen and Kesari, 2008). Despite genetic differences between the primary
GBMs that arise de novo and those that are secondary to a lower grade glioma
(reviewed in Wen and Kesari, 2008), they are morphologically indistinguishable.
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Even with newer therapies, the median survival time in patients with GBM is
about 15 months after diagnosis (Demuth and Berens, 2004).
GBMs contain areas of microvascular proliferation and necrosis, and show
much more peritumoral edema than Grade III gliomas (Wen and Kesari, 2008).
GBMs contain a central necrotic core, surrounded by a highly cellular rim, and a
peripheral infiltrative edge (Rempel and Mikkelsen, 2006). The peripheral cells
that are able to migrate away from the tumor mass are the primary cause for
dismal prognosis in GBM patients (Lefranc et al., 2005; Rempel and Mikkelsen,
2006). Most recurrences are near the site of the original tumor, indicating that
tumor cells had already infiltrated the adjacent brain by the time the initial tumor
was removed. Surgery and radiotherapy are effective in targeting the tumor
center, but not as effective against the invading cells (Louis, 2006).
In brain tumors, increased proliferation is often due to the increased
expression of growth factors or growth factor receptors, or both. This generally
occurs early in tumorigenesis (Rempel, 2001; Louis, 2006). Some of the known
growth factors associated with CNS tumors include the Platelet Derived Growth
Factors (PDGFs) and their receptors, Vascular Endothelial Growth Factor
(VEGF) and its receptors, as well as activating mutations of the Epidermal
Growth Factor Receptor (EGFR) (Rempel, 2001; Louis, 2006; Wen and Kesari,
2008). The increase in growth factor receptor activation appears to be sufficient
to induce proliferation as mutations in the signaling molecules involved in the
mitogenic pathways have not been found. However, molecules that are involved
in cell cycle control, such as the tumor suppressor genes including p27 and
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PTEN, are frequently mutated in gliomas. Mutations in these molecules allow the
cell cycle to proceed and cells continue to proliferate in response to the excess
growth factors available (Rempel, 2001). Growth factors may also be released
from the extracellular matrix if it is undergoing digestion by proteases (Rempel,
2001).

Cell Migration and Invasion
For many cell types, there are situations where active motility is a normal
function, such as in embryonic development, wound healing and immune
response. Cell motility is otherwise tightly regulated. Often in cancer, however,
this regulation is lost (Demuth and Berens, 2004). Glioma cells can invade
regionally as single cells or small clusters of cells into the adjacent brain
parenchyma, along white matter tracts, around nerve cells, and along blood
vessels. Cells can also migrate to sites distant from the primary tumor, which
occurs along distinct pathways such as the fornix or the corpus callosum (Bellail
et al., 2004; Rempel and Mikkelsen, 2006). Motility of normal cells is restricted on
white matter (Belien et al., 1999) and brain tumors that arise from other cancers
and metastasize to the brain invade only short distances from the tumor mass
(Bellail et al., 2004). This distinction indicates that glioma cells may be especially
well adapted for migration on CNS matrix. While they migrate along the blood
vessels, they do not invade into blood vessel walls or into bone and they rarely
metastasize outside the brain (Bellail et al., 2004).
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Tumor cell invasion is a complex process that involves the coordination of
several factors, including changes in cell adhesion, actin cytoskeleton
reorganization, and degradation of extracellular matrix (ECM) components
(Lefranc et al., 2005; Le Mercier et al., 2010). Cell adhesion involves cell-cell and
cell-matrix interactions and is dependent upon the interplay between adhesive
proteins and de-adhesive proteins. A shift in the balance of these proteins can
induce an intermediate state of adhesion. It is thought that cells in an
intermediate state of adhesion are the most migratory (Greenwood and MurphyUllrich, 1998). Reorganization of the actin cytoskeleton includes rearrangement
of stress fibers and formation of extensions at the leading edge including
filopodia and lamellopodia (Demuth and Berens, 2004; Lefranc et al., 2005).
Degradation of ECM proteins provides room for the cells to migrate. ECM
degradation can be achieved by a number of proteases including matrix
metalloproteases (MMPs), some members of the cathepsin family and plasmin
(Rempel, 2001; Louis, 2006).

The Matricellular Proteins
The matricellular proteins are a group of structurally unrelated proteins
that are secreted into the extracellular matrix. The term “matricellular” refers to
proteins that are found in the extracellular matrix, but do not contribute to the
ECM structure and are distinguished from bioactive proteins such as growth
factors, cytokines, and proteases (Rani et al., 2010). They are grouped based on
their ability to mediate cell-matrix interactions, which in turn affects cell function
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(Rempel and Mikkelsen, 2006). The matricellular proteins include Secreted
Protein Acidic and Rich in Cysteine (SPARC) and its homolog hevin/SC1,
tenascins-C and –X, the family of Small Integrin-Binding Ligand N-linked
Glycoproteins (SIBLINGs), the CCN1-6 family of proteins, thrombospondins-1
and -2 and some of the galectins (Rempel and Mikkelsen, 2006; Chiodoni et al.,
2010). These proteins are highly expressed during development; however,
targeted disruption of these genes in mice results in normal or near normal
phenotype (Bornstein, 2009), suggesting that they have overlapping functions.
Matricellular proteins are also highly expressed in response to injury (Rempel
and Mikkelsen, 2006; Bornstein, 2009; Chiodoni et al., 2010). They mediate deadhesion, which is characterized by restructuring of focal adhesions and actin
stress fibers, resulting in intermediate adherence (Murphy-Ullrich, 2001). This
suggests that one purpose for the de-adhesive effects caused by these proteins
may be to facilitate cell migration (Murphy-Ullrich, 2001). In addition to their
counter-adhesive effects, these proteins may also affect proliferation, apoptosis,
angiogenesis, and ECM degradation through their influence on signaling
cascades and cytoskeletal changes (Rempel and Mikkelsen, 2006).

Secreted Protein Acidic and Rich in Cysteine (SPARC)
SPARC (Sage et al., 1984), also known as osteonectin (Termine et al.,
1981) or the 40 kDa Basement Membrane protein (BM-40) (Mann et al., 1987) is
a 32 kDa secreted glycoprotein; however, post-translational modifications result
in an apparent molecular weight of approximately 43 kDa. It is developmentally
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regulated and highly expressed during vascular morphogenesis and in tissues
undergoing remodeling and repair (Lane and Sage, 1994; Sage, 1997). SPARC
is secreted into the extracellular matrix where it can modulate cell adhesion,
motility, proliferation, and ECM production (Framson and Sage, 2004). SPARC is
composed of a 17 amino acid signal sequence, an N-terminal Acidic Domain,
followed by a Follistatin-like Domain, and a C-terminal Extracellular Calcium (EC)
Binding Domain (figure 1). This signal sequence is necessary for secretion of the
protein, but is cleaved prior to secretion. The Acidic domain contains several
glutamic acid residues and binds 5-8 calcium ions with low affinity (Kd = 5 – 10
mM) (Lane and Sage, 1994). It is believed that this domain has a well defined
structure only in the presence of high amounts of calcium (Maurer et al., 1992).
When added exogenously to fibroblasts and endothelial cells in culture, the
Acidic Domain prevents cell spreading (Lane and Sage, 1990). Follistatin-like
Domains are common among matricellular proteins; they contain five disulfide
bonds and a hydrophobic core (Hohenester et al., 1997). The 5’ region of the
Follistatin-like Domain is an Epidermal Growth Factor (EGF)-like Module, which
is highly twisted by 2 of the disulfide bonds which link Cysteines 1 to 3 and 2 to 4
(Hohenester et al., 1997). The EGF-like Module has been implicated in both the
anti-proliferative and counter-adhesive activities of SPARC (Lane et al., 1994;
Lane and Sage, 1994; Sage et al., 2003). EGF-like motifs within proteins are
often involved in protein-protein interactions, though this function typically
requires calcium binding within the domain (Rao et al., 1995). The EGF-like
Module in SPARC does not bind calcium and it is not known whether this part of
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Figure 1. Structure of SPARC. SPARC is characterized by three domains. At
the N-terminus is the Acidic Domain, followed by the Follistatin-like Domain,
which contains the EGF-like Module (shown in green). The Extracellular Calcium
Binding Domain (or E-C Domain) is at the C-terminus. SPARC is glycosylated at
Asparagine 99 as indicated in the schematic. Several regions of the protein have
been extensively studied. Results from these studies are summarized at the
bottom of the figure and are described in detail in Chapter I of this report.
(Adapted from Bradshaw and Sage, 2001; reprinted with permission)
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the protein is involved in any of the protein-protein interactions known for
SPARC. It has been suggested that Follistatin-like Domains may be involved in
growth factor binding (Patthy and Nikolics, 1993). While SPARC is known to bind
some growth factors, it is not known whether this binding occurs through the
Follistatin-like Domain. Some Follistatin Domains may serve as protease
inhibitors (Hohenester et al., 1997); however no protease inhibitor activity has
been found for SPARC. The E-C Domain contains two nearly identical EF-hands
and binds two calcium ions cooperatively and with high affinity (Kd = 170 nM)
(Hohenester et al., 1996; Busch et al., 2000). EF-hands are highly conserved
Ca2+ binding motifs that act as calcium sensors in the cytosol. Since extracellular
calcium levels are high, the EF-hands of SPARC are constitutively bound to
calcium and so it is presumed that they play a structural role (Hohenester et al.,
1996). This domain appears to be essential for proper folding of the protein as
some constructs with point mutations to this domain were not secreted (Busch et
al., 2000). This domain binds to collagens and is involved in de-adhesion and
slowing of cell cycle progression (Lane and Sage, 1990; Mayer et al., 1991;
Motamed and Sage, 1998).
There have been many reports that SPARC may directly or indirectly
regulate cell proliferation. This function appears to be carried out through signal
transduction, involving a G protein-coupled receptor, which has not yet been
identified (Motamed and Sage, 1998). SPARC inhibited cell cycle progression in
bovine aortic endothelial (BAE) cells, in which cell cycle arrest occurred in early
G1 phase. In fibroblasts, the effects of SPARC were biphasic; at low levels,

9
SPARC arrested cells at the G2M phase whereas high levels of SPARC arrested
the cells in G0/G1 phase (Funk and Sage, 1993). It has been reported that
SPARC may inhibit cell growth by interfering with growth factor-receptor
interactions. SPARC can bind VEGF and PDGF and prevent them from binding
to their respective receptors (Raines et al., 1992; Kupprion et al., 1998). SPARC
also antagonizes bFGF induced proliferation; however, SPARC does not bind to
bFGF or interfere with the binding of bFGF to its receptor (Motamed et al., 2003).
SPARC can also translocate to the nucleus, however its function there is
unknown (Gooden et al., 1999).
When added to normal cells in culture, SPARC functions as a counteradhesive protein (Lane and Sage, 1994). Two mechanisms have been proposed
for these effects. The first is that SPARC binds to a receptor to initiate signaling,
resulting in focal adhesion disassembly. Stabilin-1 has been proposed as a
putative receptor for SPARC. In human macrophages, stabilin-1 binds to SPARC
and internalizes it (Kzhyshkowska et al., 2006). The mechanisms and signaling
by which stabilin-1 mediates the effects of SPARC remain to be elucidated. The
second proposed mechanism suggests that SPARC binds ECM components or
integrins to directly disrupt cell-matrix interactions, which would influence
intracellular signaling through integrin-associated proteins. SPARC binds β1
integrin and this binding involves the 3’ region of the Follistatin-like Domain
(Weaver et al., 2008). Barker et al., (2005) demonstrated that SPARC binds to
Integrin-Linked Kinase (ILK), though the mechanism for this interaction has not
yet been determined as ILK is an intracellular protein and SPARC is presumed to
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act extracellularly. This study also found that SPARC was required for
fibronectin-induced activation of ILK. Collectively, these studies indicate that
SPARC may influence cell attachment and signaling by modulating integrin
signaling. Changes in integrin signaling can lead to changes in cell adhesion and
cell shape, and can induce cell spreading and locomotion (Clark and Brugge,
1995), which will be discussed in more detail later in this chapter.

SPARC in Cancer
While SPARC has an important role in the adhesion and proliferation of
normal cells, much data suggest a role for SPARC in several cancers. It has
been demonstrated that aberrant expression of SPARC contributes to
malignancies such as melanoma (Ledda et al., 1997a; Massi et al., 1999), colon
(Porte et al., 1995), breast (Bellahcene and Castronovo, 1995; Gilles et al.,
1998), prostate (Jacob et al., 1999; Thomas et al., 2000), and ovarian cancers
(Mok et al., 1996; Yiu et al., 2001), as well as glioblastoma (Rempel et al., 1998),
and neuroblastoma (Chlenski et al., 2002). However, the role for SPARC in each
of these cancers, appears to be cell-type specific or may depend on interactions
with the tumor microenvironment (Bos et al., 2004; Podhajcer et al., 2008; Tai
and Tang, 2008; Chlenski and Cohn, 2010). SPARC expression is inversely
correlated with the degree of malignant progression in neuroblastoma (Chlenski
et al., 2002). SPARC expression in ovarian cancer is low and exposure to
SPARC inhibits proliferation in ovarian cancer cells (Socha et al., 2009). In a
breast cancer cell line, infection with SPARC-expressing adenovirus inhibited
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tumor growth and reduced invasion of these cells through Matrigel (Koblinski et
al., 2005). However, others have shown that SPARC increases invasion of breast
cancer and prostate cancer cells (Jacob et al., 1999). Increased expression of
SPARC is correlated with increased malignancy in other cancers as well. In
malignant melanoma, decreased SPARC expression by transfection with
antisense RNA resulted in the loss of the ability for these cells to adhere and
invade (Ledda et al., 1997b). Knockdown of SPARC with siRNA also decreased
glioma invasion (Shi et al., 2007). Fibroblasts and/or inflammatory cells in the
tumor microenvironment often express SPARC, which may contribute to
malignancy in some cancers (Sangaletti et al., 2008), or may be a type of normal
wound healing response to the presence of the tumor (Chiodoni et al., 2010).
The therapeutic approach to SPARC, either as a therapy or as a therapeutic
target, will depend on the specific role for SPARC in each cell type (Bos et al.,
2004).
In cancers where increased SPARC correlates with increased malignancy,
there are considerable data implicating it in the invasion process. As described
earlier, there are three major components to invasion: ECM degradation,
adhesion,

and

cytoskeletal

reorganization.

SPARC

is

associated

with

upregulation of proteinases, including MMP-1, MMP-3, MMP-9 (Tremble et al.,
1993), and MMP-2 (Gilles et al., 1998). SPARC also mediates focal adhesion
disassembly. This function is calcium-dependent (Hasselaar and Sage, 1992)
and involves a tyrosine phosphorylation-dependent pathway (Yan and Sage,
1999). Finally, SPARC induces reorganization of actin stress fibers (Yan and
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Sage, 1999). Therefore, SPARC elicits the necessary components for invasion
and in fact, it is associated with metastatic tumors (Bradshaw and Sage, 2001).
In gliomas, our lab has shown that high SPARC expression is associated
with tumor cells in the less cellularly dense areas of the tumor specimen and with
the endothelial cells of the neovessels (Rempel et al., 1998). SPARC expression
is also associated with increased expression of Membrane Type 1 – Matrix
Metalloprotease (MT1-MMP) and Matrix Metalloprotease-2 (MMP-2) in glioma
cells (Golembieski and Rempel, 2002). As in fibroblasts, SPARC has a biphasic
effect on cell cycle in gliomas. At lower levels, SPARC arrests cells in G2M phase
and at higher levels, cells are arrested in G0/G1 phase (Rempel et al., 2001).
SPARC slows cell cycle progression by mechanisms that decrease cyclins D1,
D3, A, and B (Golembieski and Rempel, 2002). It is thought that cells may
temporarily exit the cell cycle to facilitate migration (Rempel and Mikkelsen,
2006). SPARC also induces changes in cytoskeletal structure that result in
elongated morphology, which is conducive to migration (Golembieski et al.,
2008). These observations suggest a role for SPARC in the invasive aspect of
gliomas. Indeed, our lab has demonstrated that SPARC promotes glioma cell
invasion both in vitro (Golembieski et al., 1999) and in vivo (Schultz et al., 2002;
Thomas et al., 2010). SPARC may mediate glioma invasion through suppression
of cell cycle, modulation of focal adhesions, changes in cytoskeletal structure,
and changes in expression of MT1-MMP and MMP-2.

Matrix Metalloproteases
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The matrix metalloproteases (MMPs) are a homologous family of zincdependent endopeptidases, which have broad specificity for ECM proteins such
as collagen, fibronectin, and laminin (Kessenbrock et al., 2010). MMPs are
important in many cellular processes including tissue remodeling, organ
development, and regulation of inflammation. They are also involved in chronic
inflammatory diseases and cancer (Kessenbrock et al., 2010). MMPs are
synthesized as zymogens, which are held inactive by the Propeptide Domain
until it is enzymatically removed by plasmin, furin, trypsin, cathepsins or other
active MMPs (Sawaya et al., 1996; Kessenbrock et al., 2010). The gelatinases,
MMP-2 and MMP-9 are upregulated in many cancers including gliomas. There is
a low level of MMP-9 expression in normal brain, but this expression is localized
to endothelial cells. There is no expression of MMP-2 in normal brain (Tews,
2000). In glioma, MMP-2 and MMP-9 expression increases with tumor
malignancy. Expression of the gelatinases is heterogeneous throughout the
tumor and is primarily expressed by tumor cells invading into the adjacent brain
(Tews, 2000). MMP-2 may be more important in the invasive properties of
gliomas since it is expressed most intensely by the tumor cells, whereas MMP-9
is primarily expressed by proliferating endothelial cells and therefore may be
more important in angiogenesis (Forsyth et al., 1999; Raithatha et al., 2000). The
tumor microenvironment, including the neovasculature, and tumor-associated
fibroblasts and microglia, may also contribute to MMP expression at the site of
the tumor (Sawaya et al., 1996; Sameshima et al., 2000; Markovic et al., 2009).
In addition to degrading the ECM, MMPs can also cleave other extracellular
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proteins including SPARC. It is thought that differential affects of SPARC
observed among different cancers may be due to the peptides resulting from the
cleavage of SPARC (Tai and Tang, 2008). It is well documented that MMPs are
responsible for the cleavage of galectin-3 (Ochieng et al., 1994; Shekhar et al.,
2004; Toth et al., 2005) and this cleavage product has recently been proposed as
a marker for the presence of MMP activity in some cancers (Nangia-Makker et
al., 2007).

Galectin-3
The galectins are a family of evolutionarily conserved, structurally related
animal lectins, which have high affinity for β-galactosides. The 15 galectins that
have been characterized to date each contain either one or two Carbohydrate
Recognition Domains (CRDs), which are responsible for β-galactoside binding.
Galectins are localized to multiple compartments in the cell and some are
secreted, presumably through a non-classical pathway since they lack the signal
sequence required for the classical secretory pathway. Inside the cell, their
protein-protein interactions are carbohydrate independent. Extracellularly, the
galectins interact with the cell surface and the ECM (Le Mercier et al., 2010).
Galectin-3 is a mono-CRD galectin, which has a short proline, glycine, and
tyrosine – rich N-terminal domain fused to the CRD. This allows for the formation
of oligomers, which makes it unique among the mono-CRD galectins. Secreted
galectin-3 binds to the integrin receptor α1β1. This interaction may regulate cell
adhesion by preventing the interaction of α1β1 integrin with the ECM (Ochieng et
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al., 1998). In normal brain, galectin-3 expression is limited to the vasculature
(Bresalier et al., 1997; Tews, 2000); however in gliomas, galectin-3 is expressed
by the tumor cells and the level of expression increases with tumor grade
(Bresalier et al., 1997). Galectin-3 is also associated with increased resistance to
chemotherapy. This may be related to its anti-apoptotic effects. Galectin-3
contains the NGWR anti-death motif found in members of the Bcl-2 family and
has been linked to decreased apoptosis induced by cisplatin and etoposide (Le
Mercier et al., 2010).

Integrin Signaling
Integrins are a family of cell surface receptors. Integrin receptors are
heterodimers, composed of α and β subunits, which mediate cell attachment to
the ECM (Clark and Brugge, 1995; Juliano, 2002) and relay specific information
between the ECM and the cell (Kuphal et al., 2005). There are at least 24
different integrin heterodimers, which recognize different ECM components;
however there is some overlap between the integrins and the ligands they
recognize. Upon ligand binding, integrins cluster on the cell surface, which leads
to the formation of focal adhesions. The cytoplasmic domains of integrins couple
with other cytoplasmic proteins, forming large protein complexes, termed CellMatrix Adhesion Complexes (CMACs), which include cytoskeletal proteins as
wells as signaling proteins (Clark and Brugge, 1995; Juliano, 2002; Bellail et al.,
2004; Lock et al., 2008). CMACs mediate signals from inside the cell to the ECM,
termed “inside-out-signaling”, through conformational changes in the integrins,
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which modifies the affinity of integrin for the ECM proteins. They also mediate
signals from the ECM to the inside of the cell, “outside-in-signaling”, which
depends on the interactions between the integrins and the ECM proteins (Kuphal
et al., 2005; Lock et al., 2008). Integrins can also couple with other receptors
such as tyrosine kinase receptors, G protein-coupled receptors, and cytokine
receptors and can modulate the signaling pathways that are activated by these
receptors (Juliano, 2002). The interactions of integrins with a large variety of
structural and signaling molecules allow integrins to influence many facets of cell
function including cell adhesion, morphology, differentiation, proliferation,
survival, and locomotion (Clark and Brugge, 1995; Juliano, 2002; Bellail et al.,
2004).
Many of the proteins that are associated with CMACs are involved in the
dynamics of the actin cytoskeleton including vinculin, paxillin, talin, and tensin,
among others. They can also interact with proteins involved in actin dynamics
such as Arp2/3 and formins. The recruitment and/or activation of these proteins
can determine whether the actin filaments will polymerize and extend, will be
capped to prevent further polymerization, or whether a branching event will
occur. Branching and/or extension of the actin filaments and the subsequent
branches are important events in the formation of lamellipodia, filopodia and cell
migration (Pichon et al., 2004; Chhabra and Higgs, 2007; Le Clainche and
Carlier, 2008). Cell migration requires the formation of new adhesion complexes
at the leading edge of the cells and also the disassembly of adhesions at the
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trailing end. Disassembly involves the dispersal of CMAC components and
internalization of integrins (Le Clainche and Carlier, 2008; Lock et al., 2008).
Focal Adhesion Kinase (FAK) is an important mediator of integrin
signaling. Upon integrin engagement and clustering, FAK is recruited and
activated by autophosphorylation at tyrosine 397. FAK binds to adaptor proteins
through Src Homology (SH) domains, which assemble large protein complexes,
linking FAK and the integrins to the cytoskeleton and signaling molecules (Clark
and Brugge, 1995; Juliano, 2002). FAK activates Mitogen Activated Protein
Kinase (MAPK) pathways and is involved in cell survival and motility (Juliano,
2002). Increased FAK activity is associated with focal adhesion turnover and
increased cell migration (Zachary, 1997; Webb et al., 2002). SPARC-induced
invasion in glioma is mediated in part through activation of FAK (Shi et al., 2007).
Integrin signaling can also be mediated through Integrin Linked Kinase.
ILK is a serine/threonine kinase that interacts directly with the cytoplasmic
domains of β1 and β3 integrins, and modulates cell-cell and cell-matrix
interactions as well as cell contraction, spreading and migration. ILK forms
molecular complexes with proteins including Particularly Interesting CysteineHistidine-rich protein (PINCH), CH-ILKBP, affixin, paxillin and parvin. These
complexes serve as signaling platforms for integrins and growth factors and
provide a link between the ECM and the actin cytoskeleton and several signaling
pathways that impact actin (Wu and Dedhar, 2001; Legate et al., 2006). ILK can
activate or inactivate signaling pathways directly by phosphorylation of signaling
proteins including AKT and GSK3 (Glycogen Synthase Kinase) (Wu and Dedhar,
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2001). ILK can also activate Myosin Light Chain directly by phosphorylating it and
indirectly by phosphorylating inhibitors of Myosin Light Chain Phosphatase (Deng
et al., 2002), which may account for the contractile activity of ILK. Under stress
conditions, SPARC-induced activation of ILK is mediated through the binding of
SPARC to β1 integrin (Weaver et al., 2008). SPARC is also required for
fibronectin-induced ILK activation and the downstream effects of ILK on cell
contractile signaling (Barker et al., 2005).

The p38 MAPK/HSP27 Signaling Pathway
Mitogen Activated Protein Kinases (MAPKs) are a group of conserved
enzymes, which are activated by dual phosphorylation of the Thr-X-Tyr motif.
MAPKs can phosphorylate specific serine and threonine residues on many
proteins, which activate signaling pathways involved in gene expression,
proliferation, survival, differentiation, inflammation, stress response, and
migration (Huang et al., 2004; Wagner and Nebreda, 2009). There are three
groups of MAPKs, the ERKs, JNKs, and p38s, all of which are involved in cell
migration, but through different mechanisms (Huang et al., 2004). There has
been much recent evidence for p38-mediated cell migration in many cell types
(Rousseau et al., 1997; Esfandiarei et al., 2010; also reviewed in Huang et al.,
2004), including gliomas (Demuth et al., 2007; Golembieski et al., 2008). P38
MAPK mediates cell migration through paxillin, p16 Arc, and also through the
activation of MK2/3 and HSP27 (Huang et al., 2004).
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HSP27 is a member of the family of heat shock proteins, which were first
identified by their upregulation in response to heat shock. They are known for
their ATP-dependent molecular chaperone activity in response to heat shock or
oxidative stress, in which they mediate the proper folding of proteins or traffic
them to the proteosome for degradation (Ciocca and Calderwood, 2005;
Kostenko and Moens, 2009). In some cancers, HSP27 is correlated with
resistance to chemotherapy. HSP27 may confer this resistance by repairing
proteins damaged by cytotoxic chemicals and thereby protecting tumor cells from
apoptosis, making HSP27 an attractive target for therapy (Ciocca and
Calderwood, 2005).
In the unphosphorylated form, HSP27 forms multimers and can also complex
with other cytosolic proteins including p38 MAPK, MK2 and AKT (Zheng et al.,
2006; Kostenko and Moens, 2009). Several proteins have been shown to
phosphorylate HSP27 including MK2, MK3, MK5, AKT, Protein Kinase A (PKA),
PKD, and PKG (cGMP-dependent Protein Kinase). Phosphorylation of HSP27
can occur at serine-15, -78, and -82 by most of these kinases, but can also occur
at threonine-143 by PKG (Kotsenko and Moens 2009). Unphosphorylated HSP27
can localize to the barbed ends of actin filaments and act as an actin capping
protein, inhibiting actin polymerization (Huang et al., 2004; Pichon et al., 2004).
Phosphorylated HSP27 does not localize to the leading edge of lamellipodia
(Pichon et al., 2004). HSP27 phosphorylation and the uncapping of actin
filaments at the leading edge is critical to cell migration as the overexpression of
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a non-phosphorylatable mutant inhibited microfilament dependent extensions
(Piotrowicz et al., 1998).
We have previously shown that SPARC alters glioma morphology and
enhances migration on fibronectin and that these changes are mediated by the
activation of the p38 MAPK/HSP27 signaling pathway. We also demonstrated
coincident localization of SPARC and HSP27 in invading cells in xenografts of
implanted primary human tumor GBM cells (Golembieski et al., 2008). Others
have also shown that gliomas express HSP27 (Hermisson et al., 2000) and that it
increases with tumor grade (Hitotsumatsu et al., 1996). Esfandairei et al., (2010)
demonstrated in mouse aortic smooth muscle cells that activation of ILK by
PDGF caused increased cell migration through the activation of p38 MAPK.
While the migration was attributed to the transient activation of cofilin, a known
actin binding protein that enhances actin reorganization, and not to HSP27, the
ILK-mediated activation of p38 supports our working model, as follows (fig. 2A).
SPARC, through the binding of integrin β1, activates ILK. ILK then activates p38
MAPK, possibly through MAPK Kinase 3 or 6, which are known to directly
activate p38 in gliomas (Demuth et al., 2007). This results in activation of MK2
and then HSP27 phosphorylation. Phosphorylation of HSP27 reduces actin
capping and facilitates actin polymerization and cell migration (fig. 2B). In
addition, activation of the p38 MAPK/HSP27 pathway increases expression of
MMP-2 (Xu et al., 2006), which degrades the ECM to aid in cell invasion. The
Acidic Domain and the EGF-like Module of SPARC, which have been shown to
modulate cell adhesion (described earlier in the section Secreted Protein Acidic
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Figure 2. SPARC Signaling. A. SPARC signals at the cell surface, presumably
through integrin β1, and activates ILK and/or FAK, which then activate multiple
signaling pathways including the p38 MAPK/HSP27 pathway (Esfandairei et al.,
2010). Note: the signaling molecules investigated in this study are highlighted. B.
Unphosphorylated HSP27 acts as an actin capping protein, which stabilizes the
barbed end of the actin filaments, preventing actin polymerization. When
phosphorylated, HSP27 can stabilize actin filaments at the base of the
lamellipodia and facilitate polymerization (Pichon et al., 2004), which promotes
cytoskeletal structure, conducive to cell migration.
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and Rich in Cysteine), may contribute to the effects of SPARC-induced signaling
and cell migration and invasion. The deletion of these domains of SPARC may
increase cell adhesion and reduce cell migration.

Overall Hypothesis and Aim of Study
Our hypothesis is that SPARC increases glioma migration and invasion
through the activation of the p38 MAPK/HSP27 signaling pathway and the
increased expression and activation of MT1-MMP and MMP-2 and these effects
are mediated, at least in part, through the Acidic Domain and EGF-like Module.
The aims of this study are 1) to confirm, at the protein level, our previous
results from cDNA array, that SPARC increases MT1-MMP and MMP-2
expression and determine the effects of SPARC on MMP-2 activation and 2)
determine the effects of deleting the Acidic Domain and EGF-like Module on
SPARC induced migration, invasion, and signaling. The information obtained
from this study will further define the multiple functions of SPARC and give
insight into targeting SPARC as a glioma therapy.
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CHAPTER II MATERIALS AND METHODS
Cell Maintenance
All cells were maintained in a humidified chamber at 37oC and 5% CO2.
U87MG cells and the U87D8 clone were maintained in DMEM + 10% Fetal
Bovine Serum (FBS) + 1% Penicillin/Streptomycin (Pen/Strep [1:1]) + 5 µg/ml
Gentamicin. Derivation of the doxycycline-regulatable U87T2 and U87-SPARCtransfected clones A2b2 and A2bi, have been previously described (Golembieski
et al., 1999). The SPARC-transfectants (A2b2 and A2bi) and empty vector
control cells (B1b2 and C2a2) were maintained in DMEM + 10% FBS + 1%
Pen/Strep + 400 µg/ml Geneticin + 1 µg/ml puromycin. The clones transfected
with GFP and the GFP-fusion constructs were maintained in DMEM + 10% FBS
+ 1% Pen/Strep + 5 µg/ml Gentamicin + 400 µg/ml Geneticin (G418). Cell culture
reagents were purchased from Invitrogen (Grand Island, NY).

Western Blot Analyses
For collection of lysates and conditioned media, clones were plated 2 x
105 or 4 x 105 on plastic or fibronectin (FN [Millipore, Temecula, CA]) in DMEM +
10% FBS +1% Pen/Strep overnight. Clones were washed twice with PBS and
media were changed to Serum-free (SF) OptiMEM (Invitrogen, Grand Island,
NY). Media were collected at 24 hr or 48 hr, centrifuged to remove loose cells
and debris and frozen at -20oC. For collection of lysates at 3 hr, 6 hr, or 24 hr,
cells were washed twice with ice cold Phosphate Buffered Saline (PBS) and
lysed with single detergent lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-
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100) + 5 mM NaVO4 + 10 mM NaF + Easy mini protease inhibitor cocktail tablet
(Roche, Indianapolis, IN). The lysed cells were scraped, vortexed and
centrifuged. Supernatants were stored at -80oC.
For Galectin-3 studies lysates and media were collected as above. Then
media were concentrated approximately 25-fold using Centricon Plus-20
centrifugal filters Ultracel PL-10 (Millipore, Bedford, MA). The resulting media
volumes were measured by pipette and media concentrations were then
equalized by adding SF OptiMEM.
For collection of lysates from cells exposed to conditioned medium,
conditioned media were collected as described above. U87D8 cells were plated 2
x 105 on plastic in DMEM +10% FBS +1% Pen/Strep overnight. Cells were
washed twice with PBS and media were replaced with conditioned media.
Lysates were collected at 10 min, 30 min, 1 hr, 3 hr and 24 hr as described
above.
Protein concentration in the lysates was determined by BCA protein assay
(Thermo, Rockford, IL) and 8 – 20 µg protein in lysates or 20 µl media were
subject to sodium dodecyl sulfate – polyacrylamide gel electrophoresis (SDSPAGE) under reducing conditions, using 10% polyacrylamide gels. The
prestained molecular weight ladder Precision Plus Dual Color Protein Standards
(Bio Rad, Hercules, CA) or Magic Mark XP Western Standard (Invitrogen,
Carlsbad, CA) was loaded on each gel and molecular weight markings on all
Western blots in this report are given from these markers. Gels were transferred
to Immobilon-P polyvinylidene diflouride (PVDF) membranes (Millipore, Bedford,
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MA). Membranes were dried for at least 20 min and were wetted with methanol,
washed twice with Tris buffered saline (TBS) and blocked with 5% milk in TBS +
0.05% Tween-20 (TBST) for one hour at room temperature for the detection of
most of the proteins or overnight at 4oC. Membranes were probed with the
respective primary antibodies, diluted in 1 - 5% milk or 5% BSA according to the
manufacturers instructions for 1 hr at room temperature or 4oC overnight. Primary
antibodies include SPARC (1:6,000, Haematologic Technologies, Essex
Junction, VT), MT1-MMP Ab815 (1:5,000, Chemicon, Temecula, CA) and MT1MMP Cytoplasmic tail (1:10,000, Triple Point Biologics, Forest Grove, OR). The
Galectin-3 antibody (1:500) was a generous gift from Dr. Avraham Raz. Other
primary antibodies include GFP (1:2,000, Invitrogen, Eugene, OR), HSP27 and
actin (each 1:2,000, Santa Cruz Biotechnology, Santa Cruz, CA), p38 MAPK,
phospho-p38 MAPK (Thr180/Tyr182), pHSP27 Ser82 (each 1:1,000, Cell
Signaling Technology, Danvers, MA), pHSP27 Ser15 and pHSP27 Ser78 (each
1:2,000, Assay Designs, Ann Arbor, MI). Membranes were washed three times
with TBST and were incubated with the appropriate horseradish peroxidaseconjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) in
2.5% or 5% milk. Membranes were washed with TBST and subject to Enhanced
Chemiluminescence or Super Signal West Femto Enhanced Chemiluminescence
reagents (Thermo, Rockford, IL). Membranes were stripped using Antibody
Stripping Solution (Alpha Diagnostics, San Antonio, TX) or Restore Western Blot
Stripping Buffer (Thermo, Rockford, IL). Films were scanned using a HewlettPackard 8300 series scanner and images captured using Photoshop Software.
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Densitometry was measured using Image J software (National Institutes of
Health, Bethesda, MD) and values were normalized to actin. Values represent
average of three independent experiments and indicate the fold change versus
the average of the values for the two GFP-control clones.

Gelatin Zymography
Cells were plated ± FN (50 µg/ml) 5 x 105 each in one well in six-well
plates in DMEM + 10% FBS + 1% Pen/Strep overnight. Media were changed to
SF OptiMEM. Conditioned media and lysates were collected after 3 days using
an NP-40 cell lysis buffer + EZ mini EDTA-free protease inhibitor cocktail tablet
(Roche, Indianapolis, IN). Lysates were subject to BCA protein assay and 25 –
50 µg lysate was loaded on 10% SDS-PAGE gels containing 0.1% gelatin. Gels
were incubated in renaturing buffer for 30 min, rinsed 2x with deionized water
and incubated in zymogram developing buffer for 30 min. Developing buffer was
changed and gels were incubated overnight at 37oC. Gels were stained with
0.5% Coomassie Brilliant Blue (Invitrogen, Grand Island, NY) for 1 hr and
destained for 30 min – 2 hr. Gels were scanned using a Hewlett-Packard 8300
series scanner and images captured using Photoshop software.

Methods for Chapter III
RT-PCR
Cells (2 X 105) were plated for 3 days, and RNA was isolated using the
Tri-reagent kit (MRC, Inc., Cincinnati, OH) according to the manufacturer’s
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protocol. Intact RNA was verified by 1.1% formaldehyde gel electrophoresis,
quantitated, and first strand cDNA synthesis and RT-PCR were performed as
previously reported (Golembieski and Rempel, 2002) using primers for MT1MMP

(forward

5’-ATAAACCCAAAAACCCCACC-3’

ACACCCAATGCTTGTCTCC-3’)

and

CGTCTTCACCACCATGGAGA-3’

for

and

GAPDH

and

reverse
(forward

reverse

5’5’5’-

CAGGGGTCTTACTCCTTGGA-3’). GAPDH was coamplified as a normalizing
control.

Galectin-3 Processing by MT1-MMP
Recombinant human galectin-3 (from Dr. Avraham Raz) was incubated at
37°C with a recombinant catalytic domain of human MT1- MMP (Calbiochem,
San Diego, CA) in a 1:10 molar ratio of MT1-MMP to galectin-3 in 50 mM
Tris/HCl pH 7.5 buffer supplemented with 150 mM NaCl, 5 mM CaCl2 and 0.02%
Brij 35. At various times, an aliquot of the reaction containing ~40 ng of galectin-3
was collected and mixed with SDS-sample buffer. Samples were then resolved
by reducing 12% SDS-PAGE followed by immunoblot analysis using antigalectin-3 antibody recognizing full length and cleaved galectin-3.

Methods for Chapter IV
Vector Constructs, Transfection, and Clone Selection
The SPARC-GFP fusion construct was created previously in our lab
(Golembieski et al., 2008). The deletion mutants were created using the
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QuickChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA). The
PAGE-purified primers for the site-directed mutagenesis for the deletion of the
Acidic Domain (forward 5’-GGGAGGGCCTTGGCAAATCCCTGCCAGAAC-3’
and reverse 5’-GTTCTGGCAGGGATTTGCCAAGGCCCTTCCC-3’) and for the
deletion

of

the

EGF-like

Module

(forward

5’-

GTGGCGGAAAATCCCGTGTGCCAGGACCCC-3’

and

reverse

5’-

GGGGTCCTGGCACACGGGATTTTCCGCCAC-3’)

were

purchased

from

Invitrogen Life technologies (Carlsbad, CA). The PCR products were treated with
the restriction enzyme Dpn I to digest the parental plasmids. The resulting
deletion-mutant plasmids were amplified in bacteria and purified by miniprep or
maxiprep (Qiagen, Valencia, CA). Mutations were verified by enzyme digestion
and also by dye terminator sequencing (Applied Genomics Technology Center,
Wayne State University).
U87MG cells were transfected by electroporation using the nucleofector
program X-01 and solution T (Amaxa, Gaithersburg, MD). Cells were subject to
G418 selection in DMEM containing 400 µg/ml G418 for 10 days. Cells were
diluted, plated in 100-mm dishes and allowed to grow for several days. Colonies
were examined for expression of the fluorescent constructs using an Olympus
IX50 fluorescence microscope. Fluorescent colonies were circled and then
individually transferred to 24-well plates using cloning discs (Labcor Products,
Frederick, MD) soaked in trypsin. Selected colonies were observed over several
days for fluorescence to ensure a pure fluorescent clone. The clone selection
process was repeated as necessary until several clones for each construct were
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obtained. Clones were examined for expression levels by Western blot analysis
as described above and clones expressing similar levels of the constructs were
chosen. Two clones expressing each of the constructs were chosen. The clones
expressing GFP are called GFP14 and GFP72. The two clones expressing
SPARC-GFP are SPARCB8 and SPARC83. The deletion mutants include
∆AcidicG3, ∆AcidicE61, ∆EGF1.3, and ∆EGFC1. Throughout this report they will
be referred to as GFP, SPARC, ∆Acidic, and ∆EGF, respectively. In assays
where data from all clones is shown, such as Western Blots and zymograms,
note that the loading order for all data is the same throughout.
Selection of the U87D8 clone was performed using the cloning discs as
described above. Several clones were chosen and analyzed for levels of
endogenous SPARC and the ability to internalize SPARC-GFP by Western blot.
For this the clones were exposed to SF OptiMEM or conditioned medium from
one of the SPARC-GFP-expressing clones for 24 hr. From these analyses,
U87D8 was chosen for its low endogenous SPARC and ability to internalize
SPARC-GFP.

Immunofluorescence and Confocal Microscopy
For intracellular localization and actin cytoskeleton studies, 1,500 cells
were plated on coverslips coated with 50 µg/ml FN in 24 well plates in DMEM +
10% FBS + 1% Pen/Strep overnight. Clones were rinsed twice with PBS and
media were changed to SF OptiMEM for 24 hr. Cells were washed once with
PSB, fixed with 3% paraformaldehyde for 20 min, and permeabilized with 0.05%
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Triton X-100 for 5 min. Cells were washed twice with PBS, blocked with 1%
bovine serum albumin (BSA) for 30 min, and were incubated with TGN46
antibody (1:200, AbD Serotec, Oxford, UK) or phospho-Y307 FAK (1:250, BD
Biosciences, San Diego, CA). Cells were washed three times and incubated with
Cy3-labeled

goat

ant-rabbit

secondary

antibody

(1:1,000,

Jackson

ImmunoResearch Laboratories, West Grove, PA) or Cy5-labeled goat antimouse secondary antibody (1:200, Jackson ImmunoResearch Laboratories,
West Grove, PA). For cytoskeletal structure, cells were incubated in Rhodaminelabeled phalloidin (Invitrogen, Eugene, OR) for 30 min, following secondary
antibody. Cells were washed three times with PBS, once with deionized water
and mounted to slides using VECTASHIELD Hard-Set mounting medium (Vector
Laboratories, Burlingame, CA).
For colocalization studies of the constructs taken up by naïve U87D8 cells,
clones were plated at 1.8 x 105 cells per well in 6-well plates and conditioned
OptiMEM was collected as described above for Western blotting. U87D8 cells
were plated on FN-coated coverslips (2,000 cells) overnight and media were
replaced with conditioned media for 3 hr. Immunostaining was performed as
described above, using EEA1 primary antibody (1:500, BD Biosciences, San
Diego, CA) and Cy3-conjugated goat anti-mouse secondary antibody (1:1,000,
Jackson Laboratories, West Grove, PA).
Cells were imaged using a Nikon Confocal Microscope C1 System at 60X
magnification. Images were captured in 0.5 µM sections to generate single-slice
images or whole-cell built images using Nikon EZC1 2.30 software.

31

Adhesion Assay
Ninety-six-well plates were coated with FN as indicated, then blocked with
1% BSA for 1 h at room temperature. Wells were washed with PBS and cells
were plated in triplicate, 5,000 cells per well in OptiMEM, and were kept on ice
for 30 min to allow the cells to settle. Cells were incubated at 37oC for 24 hr. Nonattached cells and loosely attached cells were removed by shaking the plates on
an orbital shaker at 350 rpm for 6 min. Wells were washed with PBS and
adherent cells were fixed with 1% glutaraldehyde for 30 min. Cells were washed
3 times with PBS and stained with 0.1% crystal violet for 10 min. Cells were
washed 3 times with PBS. The color from the stained cells was solubilized in 1%
SDS and quantified by reading absorbance at 540 nm.

Wound Migration Assay
Cells were plated 3 x 105 in 60 mm dishes on 50 µg/ml FN in DMEM + 10
% FBS + 1% Pen/Strep and allowed to grow for 3 days to confluence. Wounds
were made with ¾ inch razor blades by pressing the blade into the plate to mark
the starting line and gently scraping away the cell layer. The wounds were
examined to confirm that the cell layer had been removed completely and the
plates were washed twice with PBS to remove cell debris. Media were replaced
with SF OptiMEM. Four of 6 wounds were chosen based on optimal clearing of
cells. After 20 hours, two 10x fields were imaged per wound. For each field, the
distance the cells migrated past the wounding line was the average of the
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distance measured at three locations across each image using Advanced SPOT
imaging software (Diagnostic Instruments, Sterling Heights, MI). For each
construct the distance is the average of two images per eight wounds.

Growth Curve
For each time point, cells were plated in triplicate on FN (50 µg/ml) in
DMEM + 10% FBS + 1% Pen/Strep overnight (10,000 cells per well) in 6-well
plates. Cells in triplicate wells for day 0 were counted and media were changed
on the remaining wells to SF OptiMEM. Triplicate wells were stained with 0.4%
trypan blue (Invitrogen, Grand Island, NY) and counted using a hemacytometer
at 24 hr and 48 hr.

Transwell Migration and Invasion Assays
For migration assays, 5 x 104 cells were plated in triplicate in SF
OptiMEM, in Corning transwell inserts with 8-µM pores (Fisher Scientific,
Pittsburg, PA). Cells were allowed to settle to the bottom of the transwell for 15
min at 37oC; then the lower chambers were filled with OptiMEM containing 10%
FBS to stimulate migration. Migration was stopped after two hours. For invasion
assays, transwell inserts were coated with 50 µg/well Matrigel (BD Biosciences,
Bedford, MA) for one hour at 37oC. Cells were plated 5 x 104 cells per well in SF
OptiMEM and lower chambers were filled with OptiMEM + 10% FBS. Invasion
assays were stopped after 24 hr. Cells and Matrigel were removed from the top
of the filters with cotton swabs. Cells on the underside of the filters were fixed

33
with 10% neutral buffered formalin for 3 min, rinsed with deionized water, and
stained with hematoxylin for 6 min. The filters were rinsed in tap water, blued in
ammonia water and rinsed again. Filters were stored in tap water until imaged.
Cells were imaged using an Olympus IX81 microscope attached to a
DP70 digital camera. Five fields per filter were imaged at 10X for migration or 12
fields at 20X for invasion. Nuclei were counted and the number of cells per field
was averaged for each well. Results represent average number of cells per field
± standard deviation for three experiments.

Statistical Analyses
For the wound and transwell assays, the means for each construct were
compared using generalized linear mixed models, which adjusted for the
variability between clones expressing the same construct. One-way analysis of
variance was used for the Western Blots. The growth curve and the adhesion
assay were analyzed using the Student’s t-test. Differences were considered
significant when p < 0.05.
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CHAPTER III SPARC UPREGULATES MT1-MMP EXPRESSION, MMP-2
ACTIVATION, AND THE SECRETION AND CLEAVAGE OF GALECTIN-3 IN
U87MG GLIOMA CELLS
Introduction
Tumor cell invasion involves the coordination of changes in cell adhesion,
actin cytoskeleton reorganization, and degradation of extracellular matrix
components (Lefranc et al., 2005; Le Mercier et al., 2010). Proteases including
matrix metalloproteases (MMPs), some members of the cathepsin family and
plasmin are often upregulated in tumor cells in order to facilitate invasion
(Rempel, 2001). High levels of SPARC have been correlated with the increased
expression of specific MMPs. Exposure to SPARC increased expression of
MMP-1 (collagenase), MMP-3 (stromelysin), and MMP-9 (gelatinase B) in
cultured rabbit synovial fibroblasts (Tremble et al., 1993). In addition, SPARC has
been correlated with tumor invasion in several different types of cancer
(Bradshaw and Sage, 2001; Framson and Sage, 2004), where ECM and
basement membrane degradation during tumor cell invasion may be one
mechanism enabling enhanced invasion. SPARC was found to increase MMP-2
activation in breast cancer cell lines (Gilles et al., 1998). In addition, using a
genetic model of glioma invasion, SPARC expression was associated with
increased levels of MMP-3 and MMP-9, but inhibitor studies identified MMP-3 as
the major protease involved in promoting glioma invasion through a Matrigel
substrate (Rich et al., 2003).
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Interestingly, MMPs appear to regulate the function of SPARC as well.
MMPs, including collagenase-3 (MMP-13), MMP-2, MMP-9, matrilysin (MMP-7),
and stromelysin-1 (MMP-3) can cleave SPARC, and the cleaved product shows
an increased affinity for collagen (Sasaki et al., 1997). Furthermore, proteolytic
cleavage of SPARC has been observed in vivo, suggesting a specific biological
function for its cleavage products (Sasaki et al., 1997).
Galectin-3 is a 31-kDa member of the family of β-galactoside binding
lectins (Houzelstein et al., 2004) that modulates normal development (Ochieng et
al., 2004), and several biological processes involved in cancer, including
apoptosis (Nakahara et al., 2005), tumor invasion, and metastasis (Califice et al.,
2004; Krzeslak and Lipinska, 2004). Galectin-3 has been localized to the nucleus
and cytosol, but is also secreted into the ECM where it mediates cell-cell and
cell-matrix interactions. Galectin-3 is made up of two domains. The C-terminal
domain is the carbohydrate binding domain (CRD). The N-terminal domain,
which is important for galectin-3 dimerization (Shekhar et al., 2004), is made up
of Gly-X-Tyr repeats, which are characteristic of collagen, and make the protein
susceptible to proteolysis by MMP-2, MMP-9 (Ochieng et al., 1994; Shekhar et
al., 2004) and the MT1-MMP soluble fragment (Toth et al., 2005). Thus, cleavage
of galectin-3 is considered to be an indicator of MMP-2, -9, and MT1-MMP
activity (Toth et al., 2005; Nangia-Makker et al., 2007). The processing of
galectin-3 results in the generation of 22-kDa and/or 27-kDa degradation
products that include the CRD and maintain carbohydrate binding activity
(Ochieng et al., 1994; Shekhar et al., 2004; Toth et al., 2005). Thus, cleavage of
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galectin-3 by MMPs may be an additional function of the proteinases to regulate
galectin-3 activity (Ochieng et al., 1994).
Our laboratory has demonstrated that SPARC is highly expressed in
invading brain tumors (Rempel et al., 1998; Rempel et al., 1999; Vajkoczy et al.,
2000) and that SPARC induces tumor invasion in vitro (Golembieski et al., 1999)
and in vivo (Schultz et al., 2002). cDNA array analysis indicated that upregulation
of SPARC caused an increase in MMP-2 and MT1-MMP transcript abundance,
2.2- and 2.3- fold respectively, when transfected into U87MG glioma cells
(Golembieski and Rempel, 2002). Therefore, to confirm these findings at the
mRNA and protein level and to determine whether SPARC also contributes to
increased MMP activity, we used RT-PCR and Western blot analysis to assess
the levels of MT1-MMP and gelatin zymography to assess the levels of latent and
active MMP-2. We also examined galectin-3, a target of MT1-MMP and MMP-2,
as a marker of MMP activity.
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Results
SPARC Expression is Associated with Increased MMP-2 Levels and Activity
We performed Western blot analysis of equally plated cells (fig. 3A) to
measure the level of expression of SPARC in the cell lysates and in the
conditioned media of the SPARC-expressing A2bi and A2b2 cell lines and the
control vector-transfected cell lines, B1b2 and C2a2. The blots indicate that A2bi
and A2b2 indeed express and secrete greater levels of SPARC than the control
cells. The actin signal demonstrates equal loading of the protein for the cell
lysates.
Gelatin zymography (fig. 3B) of the lysates and conditioned media of
SPARC-transfected and control vector-transfected cells indicates that the
SPARC-transfected cells, A2bi and A2b2, express more latent and active species
of MMP-2. The control cells, B1b2 and C2a2, expressed mainly the latent
species of MMP-2, with low to undetectable levels of active MMP-2. The levels of
active MMP-2 in cell lysates as well as the levels of the intermediate bands in the
conditioned medium were quantified by densitometry (levels of active MMP-2 in
the conditioned media were too weak to quantify). Figure 3C shows the total
amount of processed MMP-2 in lysates and conditioned medium and further
illustrates the increase in activation of MMP-2 in the presence of SPARC.

SPARC Expression is Associated with Increased MT1-MMP Levels
We next examined the expression of MT1-MMP because we had
observed increased transcript abundance by cDNA array analysis (Golembieski
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Figure 3. Increased SPARC correlates with increased MMP-2 expression
and activity. (A) Western blot analysis demonstrating increased SPARC in
lysates and conditioned media of SPARC-(A2bi, A2b2) versus control-(B1b2,
C2a4) transfected cells. +C/SPARC indicates SPARC positive control. Actin was
used as a loading control. (B) Gelatin zymography demonstrating increased
MMP-2 expression and activation in lysates and conditioned media of SPARCversus control-transfected cells. +C/MMP2 and +C/MMP9 indicate MMP-2 and
MMP-9 positive controls. The latent, intermediate, and active forms are indicated.
(C) Densitometric analysis indicates increased active MMP-2 in the lysates (L)
and intermediate MMP-2 in the conditioned medium (CM) of the SPARC- versus
control-transfected cells (the active MMP-2 signals in CM were too weak to
quantitate). Representative results from n = 3 experiments are shown.
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and Rempel, 2002), and because MT1-MMP, along with TIMP-2, is the
physiological activator of MMP-2. Using RT-PCR, increased levels of MT1-MMP
transcript were observed in SPARC-transfected cells compared to controltransfected cells (fig. 4A). We further confirmed the increase in MT1-MMP with
SPARC at the protein level using Western blot analysis. The protein was
detected using both the anti-MT1-MMP antibody, which detects the cytoplasmic
tail, and the Ab815 MT1-MMP antibody that detects the hinge region (fig. 4A).
The membranes were reprobed with an anti-actin antibody, which indicates that
there was equal loading among the lysate samples (fig. 4A). Note: The lane for
the protein standard was moved closer from another region of the same blot.
MT1-MMP protein levels as detected with both antibodies were higher in the
SPARC-transfected cells, A2bi and A2b2, compared to control cells, B1b2 and
C2a2. Densitometry results indicated that the SPARC-transfected cells had > 2fold increase in MT1-MMP transcript (fig. 4B) and protein (fig. 4C) in SPARCtransfected cells when compared to control cells.

Galectin-3 Processing by MT1-MMP
Galectin-3 is cleaved by MMP-2 and MMP-9 at the Ala62-Tyr63 peptide
bond generating a ~22-kDa fragment (Ochieng et al., 1994). Toth et al. (2005)
reported increased galectin-3 processing in the presence of MT1-MMP. This
processing was attributed to MT1-MMP activity since it was inhibited by the
addition of TIMP-2, but not TIMP-1. However, the kinetics and cleavage site of
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Figure 4. SPARC increases expression of MT1-MMP. (A) RT-PCR indicates
an increase in MT1-MMP transcript in SPARC-(A2b1, A2b2) versus control(B1b2, C2a2) transfected cells. GAPDH serves as the internal control. Western
blot analysis shows increased MT1-MMP in SPARC- versus control-transfected
cells using the AB-815 antibody to the hinge region or the antibody to the
cytoplasmic tail. Actin was used as a loading control (only one actin blot is
illustrated). Note: The lanes for the protein standard were moved closer from
another region of the same blots. Densitometric analyses, demonstrating
increased MT1-MMP transcript (B) and protein [densitometry for the cytoplasmic
tail antibody shown (C)] in the SPARC- versus control-transfected cells.
Representative results from n = 3 experiments. Base pairs and molecular weights
are marked at the left of (A).
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MT1-MMP-dependent galectin-3 degradation were not reported. Here we
examined the kinetics of galectin-3 degradation by MT1-MMP in a purified
system and determined the N-terminal sequence of the cleaved product. To this
end, recombinant galectin-3 was incubated with a recombinant catalytic domain
of human MT1-MMP and aliquots of the reaction were collected at various times
for immunoblot analysis. As shown in figure 5, MT1-MMP cleaved galectin-3 (31kDa) to a ~22-kDa product in a time-dependent manner. The ~22-kDa
degradation product was readily detected after 10-min incubation and after two
hours most of the galectin-3 was converted to the degradation product. Nterminal sequencing of the 22-kDa fragment revealed an N-terminus starting with
Tyr63 consistent with a cleavage at the Ala62-Tyr63 peptide bond. Taken together,
these results establish galectin-3 as an MT1-MMP substrate via a cleavage site
that is also targeted by MMP-2 and MMP-9 (Ochieng et al., 1994).

SPARC Expression is Associated with Increased Galectin-3 Secretion and
Cleavage
Since galectin-3 is a target of MMP-2 and MT1-MMP, we next examined
protein levels of galectin-3, including the 31-kDa and the proteolytically
processed forms. Western blot analysis of cell lysates show similar levels of
galectin-3 in the SPARC-transfected and control vector-transfected cells, and
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Figure 5. MT1-MMP cleaves galectin-3. Recombinant human galectin-3 was
incubated with a recombinant catalytic domain of human MT1-MMP in a 1:10
molar ratio of MT1-MMP to galectin-3. Samples were taken at the indicated time
points and resolved by reducing 12% SDS-PAGE followed by Western blot
analysis using the anti-galectin-3 antibody recognizing full-length and cleaved
galectin-3. Molecular weights are marked at the right of the blot.
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only the 31-kDa unprocessed galectin-3 is present (fig. 6A). Actin shows equal
loading of the lysates (fig. 6A). Densitometric analysis shows no change in
galectin-3 in lysates associated with different SPARC protein levels (fig. 6C). In
contrast, Western blot analysis of conditioned media indicates the presence of
the 31-kDa galectin-3, as well as the 27-kDa and 22-kDa cleaved forms (fig. 6B).
The densitometry analysis illustrates the levels of total galectin-3, with relative
levels of the 31-kDa galectin-3 (black), the 27-kDa cleaved form (grey), and the
22-kDa form (white) illustrated for each cell line (fig. 6D). The Western blot and
densitometric analyses show increased secretion of full-length galectin-3 and
of the 27-kDa and 22-kDa forms in the SPARC-transfected cells versus control
cells. The increase in secretion of the full-length galectin-3 does not completely
account for the increase in galectin-3 processing, as there is a greater
percentage of the cleaved forms in the SPARC-transfected cells than in the
control cells (fig. 6D), thus indicating an increase in protease activity with
increased SPARC expression.
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Figure 6. SPARC increases galectin-3 secretion and cleavage. (A) and (C)
Western blot and densitometric analysis demonstrating no change in galectin-3
levels in lysates of SPARC-(A2bi, A2b2) versus control-(B1b2, C2a2) transfected
cells. Actin (A) is the loading control used for normalization in (C). (B) and (D)
Western blot and densitometric analysis showing the increase of full-length and
both cleaved form of galectin-3 in conditioned media from SPARC- versus
control-transfected cells. The relative levels of the 31-kDa (black), the 27-kDa
(gray), and the 22-kDa (white) proteins are illustrated (D). The bars in total
indicate relative levels of total secreted galectin-3 by each cells line.
Representative results from n = 3 experiments. Molecular weights are given at
the left of each blot.
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Discussion
Our laboratory and others have shown that increased SPARC expression
correlates with glioma cell invasion in vitro (Golembieski et al., 1999) and in vivo
(Schultz et al., 2002; Rich et al., 2003). In vivo, we observed increased SPARC
expression promoted tumor invasion along blood vessels, and as individual cells
invading the corpus collosum and adjacent brain tissue (Schultz et al., 2002). Our
cDNA array analysis suggested that SPARC may promote invasion by altering
the expression of proteases involved in extracellular matrix degradation,
particularly MT1-MMP and MMP-2 (Golembieski and Rempel, 2002). In this
study, we confirm that SPARC expression induces upregulation of MT1-MMP,
increased expression and activation of MMP-2, and increases in the secretion
and cleavage of galectin-3, a target of both MT1-MMP and MMP-2. Although the
exact means whereby SPARC increases the expression of these proteins is
unknown, these data provide a mechanism whereby SPARC promotes glioma
invasion by increasing the degradation of the surrounding ECM via MMP
activation and/or altering tumor cell adhesion and motility via galectin-3 secretion
and/or cleavage.
The role of MMPs in glioma invasion is well documented (Rao, 2003;
Bellail et al., 2004; Demuth and Berens, 2004). MMP-9 and MMP-2 have been
studied extensively. Differential roles have been suggested whereby MMP-9
contributes primarily to invasion along established blood vessels, but MT1-MMP
and MMP-2 may regulate both invasion and angiogenesis (Forsyth et al., 1999).
In gliomas, MT1-MMP expression correlates with tumor grade (Nakada et al.,
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1999; Nuttall et al., 2003) and invasiveness (Guo et al., 2005). MT1-MMP
promotes invasion of C6 glioma cells on the normally restrictive central nervous
system white matter (Belien et al., 1999). Activation of pro-MMP-2 requires MT1MMP and TIMP-2 (Gingras et al., 2000) and transfection of U251 cells with MT1MMP displayed prominent activation of MMP-2 and increased invasive growth in
vitro (Nakada et al., 2001).
SPARC has been implicated in the upregulation of MMP-2. Gilles et al.
(1998) reported that increased SPARC levels correlated with increased activation
of MMP-2 in breast cancer cell lines. They did not see a change in the steady
state levels of MT1-MMP mRNA or protein; however, they did detect a decrease
in the levels of TIMP-2 protein in the media of SPARC-expressing cells. This is in
contrast to our study, where increased SPARC expression was associated with
an increase in MT1-MMP transcript and protein levels, but TIMP-2 levels in the
media did not correlate with SPARC expression (data not shown). The presence
of both the activating enzyme and the endogenous inhibitor must be considered,
since both are involved in the regulation of MMP-2 activity (Kessenbrock et al.,
2010). Differences may be attributed to the different cell lines used in these
studies.
Interestingly, Xu et al., (2006) demonstrated that TGF-β upregulates MMP-2
through increased activation of the p38 MAPK/HSP27 signaling pathway. We
have demonstrated that SPARC increases glioma invasion through activation of
the p38 MAPK/HSP27 pathway (Golembieski et al., 2008). Others have shown
that SPARC regulates TGF-β signaling through Smad-2 and JNK by binding to
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the TGF-β/receptor complex (Francki et al., 2004). While it is not known whether
SPARC and TGF-β cooperate in activation of the p38 MAPK/HSP27 signaling
pathway, this does provide a possible mechanism by which SPARC upregulates
MMP-2 expression.
The increase in MMP-2 we observed in the SPARC-transfected U87MG
cells was also observed in another genetically defined model of SPARC-induced
glioma invasion (Rich et al., 2003). SPARC expression in low-grade astrocytoma
cells harboring SV40 large T Ag, hTERT, and oncogenic Ha-Ras was associated
with increased MMP-9, MMP-3, and a modest increase in MMP-2. Invasion
through Matrigel was attributed to MMP-3. The use of a non-specific MMP2/MMP-9 protease inhibitor suggested that invasion was not mediated by either
of these proteases. However, the effects of the modest increase in MMP-2, and
its effects on invasion may have been clouded by the expression of the other
MMPs. That study did not evaluate MT1-MMP or TIMP-2 expression.
A benefit to the U87MG cell line is the lack of MMP-9 expression, thereby
eliminating any confounding effects of its expression, especially with respect to
cleavage of galectin-3 (Ochieng et al., 1994). Our data suggest that SPARCinduced upregulation and activation of MT1-MMP and MMP-2 may indeed
contribute to SPARC-induced invasion, by degradation of surrounding ECM, and
possibly through the modulation of tumor cell adhesion and/or motility by the
increased secretion and cleavage of galectin-3.
Although the secreted lectin galectin-3 has been implicated in the
regulation of growth, invasion, and metastasis of human tumors, differences have
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been observed depending on the tumor type. For example, galectin-3 expression
is downregulated in prostate, ovarian, and breast cancers, but upregulated in
gastric cancers and hepatocellular carcinoma (Califice et al., 2004). However, as
described for breast cancer, the overall decrease in galectin-3 expression was
accompanied by a localized expression to peripheral tumor epithelial cells that
are associated with the acquisition of the invasive phenotype (Shekhar et al.,
2004). Therefore, increased expression in this subset of tumor cells correlated
with tumor progression.
Galectin-3 is expressed in a number of glioma cells lines (Lahm et al.,
2001). However, reports on the expression of galectin-3 in gliomas have also
been conflicting. Bresalier et al., (1997) reported that the level of galectin-3
expression increases during glioma progression. Subsequent studies have found
a global decrease in expression (Gordower et al., 1999; Camby et al., 2001).
However, higher galectin-3 expression was also associated with the invasive
regions in vivo, and GBM cells exhibited greater motility on galectin-3 in vitro,
suggesting that increased galectin-3 promoted invasion (Camby et al., 2001). In
addition, galectin-3 expression is not restricted to the tumor cells. Indeed,
galectin-3 expression from other normal cell sources must also be considered, as
heterogeneous expression within the tumors results from various cell types
including microglia and endothelial cells (Strik et al., 2001).
Data relating to effects of galectin-3 on adhesion and motility are also
conflicting. Debray et al., (2004) demonstrated that inhibition of galectin-3
expression did not alter U373 adhesion on several ECM proteins or invasion

49
through Matrigel, and only increased migration on laminin. In contrast, John et al.
(2003) found that treatment of breast cancer cells with a recombinant Nterminally truncated galectin-3, which functions as a dominant-negative inhibitor
of galectin-3-induced cell adhesion, decreased tumor growth and metastasis in
an in vivo model of breast cancer. Whether these differences reflect cell typespecific differences remains to be determined.
Differences in the reports correlating galectin-3 in gliomas and other
cancer types may also be due to the different antibodies used to detect galectin3, and their ability to detect the cleaved fragment. The increasing expression of
MMP-2 and MMP-9 associated with glioma and other cancer progression could
result in more cleavage of galectin-3. Antibodies incapable of detecting the
cleaved fragment would underestimate the amount of galectin-3 fragment
present. Of significance, none of these studies differentiated between the native
and cleaved forms of the protein. Since the cleaved fragment is present and
stable in vivo and it can compete for cell surface or ECM binding, it has been
speculated that cleavage would result in change in biological function such as
alterations of cell adhesion and motility (Ochieng et al., 1998). Our results show
that there is an increase in galectin-3 secretion by the more invasive SPARCexpressing cells, and much of the secreted protein is cleaved. Galectin-3
cleavage in these cells is likely to be mediated by MMP-2 and/or MT1-MMP.
Here we confirmed that MT1-MMP can readily accomplish the degradation of
galectin-3 to the ~22-kDa product by hydrolyzing the same peptide bond cleaved
by gelatinases.
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In summary, our results show that SPARC plays a role in expression of
MT1-MMP and MMP-2. Galectin-3 secretion and cleavage is also increased in
cells expressing high levels of SPARC. Taken together, increased MMP
activities, increased galectin-3 secretion, and the subsequent increase in the
proteolytic processing of galectin-3 provide mechanisms by which SPARC
increases tumor cell invasion.

51
CHAPTER IV DELETION OF THE SPARC ACIDIC DOMAIN OR EGF-LIKE
MODULE REDUCES SPARC-INDUCED MIGRATION

AND SIGNALING

THROUGH THE P38 MAPK/HSP27 PATHWAY
Introduction
There is much evidence that SPARC plays different roles in different
cancers (reviewed in Bos et al., 2004; Tai and Tang, 2008; Chlenski and Cohn,
2010). It is believed that some of the differences may be due to differential
processing in the microenvironment of different tumor types. SPARC can be
proteolytically cleaved by MMPs and plasmin and the cleavage products have
altered affinity for collagen and exhibit differential effects on proliferation and
migration (Lane et al., 1994; Sasaki et al., 1997; Sage et al., 2003). There have
been numerous studies investigating the specific roles of SPARC peptides in
various cell types (fig. 1).
A peptide corresponding to a portion of the Acidic Domain (fig. 1) inhibited
cell spreading and an antibody to this peptide blocked the anti-spreading activity
of wt-SPARC (Lane and Sage, 1990). This peptide also caused a partial
decrease in focal adhesion-positive endothelial cells (Murphy-Ullrich et al., 1995).
The N-terminal peptide also contributes to SPARC-mediated changes in gene
expression. When added to angiogenic endothelial cells in culture, this peptide,
like wt-SPARC, down-regulated thrombospondin and FN and induced the
expression of PAI-1 (Lane et al., 1992). This peptide also induced MMP-2
activation in breast cancer cells (Gilles et al., 1998). The N-terminal peptide had
no effect on endothelial cell proliferation (Funk and Sage, 1991).

The

Acidic
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Domain is absent or truncated in lower organisms and it is predicted that it
evolved to facilitate interactions with ECM components (Koehler et al., 2009).
These data indicate that this region of the protein is necessary for some of the
activities of SPARC.
The N-terminal region of the Follistatin-like Domain includes an EGF-like
Module (fig. 1). Peptides mimicking the EGF-like Module caused focal adhesion
disassembly when added to endothelial cells in culture (Murphy-Ullrich et al.,
1995). This peptide inhibited endothelial cell proliferation (Funk and Sage, 1991)
and had a biphasic effect on fibroblast proliferation (Funk and Sage, 1993). A
similar peptide derived from the digestion of SPARC by MMP-3, had a biphasic
effect on endothelial cell proliferation (Sage et al., 2003). The EGF-like Module
peptide was also a more potent competitor for SPARC binding to the cell surface
of endothelial cells than the wt-SPARC protein (Yost and Sage, 1993). This
region also inhibited angiogenesis induced by neuroblastoma cells in a dosedependent manner (Chlenski et al., 2004). Another region of the Follistatin-like
Domain of SPARC, which is downstream of the EGF-like Module, was shown to
stimulate proliferation of both endothelial cells and fibroblasts (Funk and Sage,
1993). This C-terminal region of the Follistatin-like domain is also the region of
SPARC that binds to β1 integrin (Weaver et al., 2008).
A peptide corresponding to the second EF-hand in the E-C Domain (fig. 1)
disrupted focal adhesions in endothelial cells (Murphy-Ullrich et al., 1995). This
peptide also inhibited cell spreading and showed calcium-dependent binding to
collagens (Lane and Sage, 1990). This EF-hand has been shown to bind to the
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endothelial cell surface with similar affinity as wt-SPARC (Yost and Sage, 1993)
and inhibit proliferation of endothelial cells, which was also calcium dependent
(Sage et al., 1995). This domain is also important in the proper folding of
SPARC, as some constructs containing point mutations were not secreted
(Busch et al., 2000).
We have previously shown that SPARC expression increases glioma cell
migration on FN in vitro (Golembieski et al., 2008). The increased migration of
these cells is not simply due to the counter-adhesive properties of SPARC since
SPARC does not significantly alter glioma cell attachment to fibronectin (Rempel
et al., 2001). We have demonstrated that SPARC increases migration through
the activation of the p38/HSP27 signaling pathway (Golembieski et al., 2008). As
shown in figure 2, at the cell surface, secreted SPARC binds to integrin β1 (Nie
et al., 2008; Weaver et al., 2008), which then activates ILK. Activation of ILK
affects several pathways, including p38 MAPK (Esfandiarei et al., 2010). P38
exists in a complex with MK2, AKT and HSP27, in their inactive states. These
signaling complexes often occur in cells and it is thought that the purpose of the
complex is to facilitate rapid activation of the pathways (Zheng et al., 2006).
Upon activation, p38 can phosphorylate MK2, which then can phosphorylate
HSP27 (Guay et al., 1997). MK2 can also activate AKT in this complex (Rane et
al., 2001; Wu et al., 2007) and AKT can activate HSP27 directly (Zheng et al.,
2006). Once HSP27 is phosphorylated, it dissociates from the complex (Rane et
al., 2001; Zheng et al., 2006). HSP27, in its unphosphorylated form, participates
in actin capping to prevent actin polymerization (Guay et al., 1997). When HSP27
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is phosphorylated, it no longer localizes to the leading edge of the lamellipodia,
but localizes further back, where it stabilizes the actin filaments and prevents
depolymerization in order to facilitate migration (Guay et al., 1997; Schafer et al.,
1999). Expression of SPARC in glioma increases p38 MAPK activation and also
increases the expression and phosphorylation of HSP27. Inhibition of HSP27
phosphorylation using a p38 MAPK selective inhibitor or knockdown of HSP27
with siRNA results in decreased migration and/or invasion of glioma cells in vitro
(Golembieski et al., 2008).
These studies prompted us to ask what specific roles the Acidic Domain
and the EGF-like Module have in glioma migration, invasion and signaling. Since
SPARC expression is high in gliomas (Rempel et al., 1998), we expressed
deletion mutant constructs of SPARC in glioma cells as opposed to exposing the
glioma cells to the purified proteins. Using deletion mutants of a SPARC-GFP
fusion construct, we investigated the effects of deleting these regions of SPARC
on glioma migration, invasion, MMP-2 activity, and signaling. Based on our
studies and previously reported peptide studies, the two deletion mutant
constructs were predicted to increase cell adhesion due to a loss or decrease in
the ability to disrupt focal adhesions. Furthermore, changes in the interactions of
these mutants with integrins would alter SPARC-induced signaling through
integrin-mediated pathways, as outlined in figure 2, including ILK and FAK and
their downstream signaling pathways, p38 MAPK/HSP27, SHC/RAF/ERK, and/or
RHO/ROCK/MLC. Altered signaling through these pathways would result in
changes in SPARC-induced migration and invasion.
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Results
Transfection, Expression, and Secretion of the Constructs in U87MG Cells
While the second EF-hand of SPARC is important in SPARC function
(Framson and Sage, 2004), it is also important in the proper folding of the protein
(Busch et al., 2000). Therefore, this study focuses on the Acidic Domain and the
EGF-like Module portion of the Follistatin-like Domain. Since most of the effects
of SPARC are presumed to occur extracellularly, the 17 amino acid N-terminal
signal peptide was also left intact to ensure that the constructs would be
secreted. The SPARC-GFP fusion plasmid was created previously in our lab
(Golembieski et al., 2008). The deletion mutant constructs (fig. 7) were created
from this plasmid using site-directed mutagenesis. The Acidic Domain deletion
mutant (∆Acidic) was created by deleting base pairs 209 – 264, corresponding to
amino acids 1 – 52. The deletion of this entire domain was expected to have little
effect on the proper folding of the construct, since it is loosely folded in native
SPARC. For the EGF-like Module deletion mutant construct (∆EGF), base pairs
271 – 336 were deleted, corresponding to amino acids 55 – 76. This deletion
includes four cysteines, which in native SPARC, form two disulfide bonds within
this region (Cys 1 – 3 and 2 – 4) (Hohenester et al., 1997). The deletion of the
four cysteines, which participate in these two disulfide bond pairs, was intended
to promote proper folding of the remaining part of the protein since the protein
contains ten additional cysteines; all of which are disulfide bonded (5 – 9, 6 – 8, 7
– 10, 11 – 12, and 13 – 14) (Hohenester et al., 1996; Hohenester et al., 1997).
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Figure 7. Schematic of the deletion constructs. Wildtype SPARC-GFP (A)
contains the Acidic Domain (black), Follistatin-like Domain (red) which includes
the EGF-like Module (yellow) and the E-C Domain (dark blue). ES (light blue)
indicates the export signal, which is not part of the mature protein, and GFP
(green) refers to the C-terminal GFP tag. (B) The Acidic Domain deletion mutant
construct (∆Acidic) has amino acids 1 – 52 of the mature protein deleted. (C) The
EGF-like Module deletion mutant construct (∆EGF) has amino acids 55 – 76 of
the mature protein deleted.
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The GFP empty vector (GFP), wt-SPARC-GFP (herein referred to as
SPARC or SPARC-GFP), and the deletion constructs (∆Acidic and ∆EGF) were
transfected into U87MG cells and stable clones were selected. Expression was
verified by fluorescence microscopy (fig. 8). The fluorescence images show that
cells expressing GFP show fluorescence throughout the cell, while in cells
expressing SPARC-GFP the fluorescence appears perinuclear, which is
expected since SPARC is secreted through the classical pathway (Mason et al.,
1986). Both of the deletion mutant constructs demonstrate similar intracellular
localization to the wild-type SPARC-GFP.
Two clones were chosen for each construct based on the level of
expression and secretion. The level of expression of the respective constructs in
the lysates and conditioned medium, as well as the low level of endogenous
SPARC are indicated by Western blotting in figure 9. Western blots in figure 9A
and C were probed with an anti-SPARC antibody and indicate the level of
expression and secretion of the SPARC-GFP and the ∆EGF construct as well as
the levels of endogenous SPARC expressed (fig. 9A) and secreted (fig. 9C) by
the clones. The epitope that the anti-SPARC antibody recognizes is within the
Acidic Domain; therefore the ∆Acidic construct is not recognized by the SPARC
antibody. Expression and secretion levels of all four constructs can be seen
when the blots are probed using an anti-GFP antibody (fig. 9B and D).
Expression levels of the constructs in the clones are similar. GFP is not secreted
as indicated (fig. 9D). We expected that both deletion mutant constructs would be
secreted since the export signal was not disrupted in either deletion. However,
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Figure 8. Expression of the constructs in the selected clones. Top panels
show 40X fluorescence images (one clone for each construct is shown)
indicating that the clones express the constructs and that the constructs have a
functional GFP-tag. Middle panels are phase contrast images of the same field.
Bottom panels are merged images of the top and middle panels indicating the
fluorescence within the cells. Insets show 160X zoomed images for clarity.
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Figure 9. Levels of expression and secretion of the constructs. Western blot
analyses of cell lysates (A and B) and conditioned medium (C and D) indicate the
level of expression and secretion of the constructs as well as the levels of
endogenous SPARC in each of the clones. The parental cell line, U87MG, is
represented in lane 1 of each blot. Blots were probed using an anti-SPARC
antibody (A and C), which shows the levels of endogenous SPARC, SPARCGFP and ∆EGF, but does not detect ∆Acidic. Blots were stripped and reprobed
using an anti-GFP antibody (B and D), which detects all of the constructs. The
intermediate bands observed in A and C are specifically detected by the SPARC
antibody and are believed to be due to alternate processing or proteolytic
cleavage. Actin indicates equal loading of cell lysates. Molecular weights are
shown at the left of each blot.
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while the expression levels, in the lysates, of ∆Acidic were similar to SPARC and
∆EGF, the levels in the conditioned medium were consistently lower than that for
SPARC and ∆EGF. Since the Acidic Domain is in close proximity with the export
signal, deleting this region may affect secretion.
In creating deletion mutant constructs, proper folding of the constructs was
a concern. Since SPARC does not have specific catalytic activity or activation
state, there is not a method to clearly prove that effects of the deletion mutants
on the cells are not due to misfolding of the constructs. However, both deletion
mutant constructs are secreted and run at the expected size on Western blot,
which suggests that they are glycosylated and properly folded. The next
experiments, in addition to characterizing the deletion mutants, provide further
evidence for proper folding.

Perinuclear Localization of SPARC-GFP and the Deletion Mutants
To better demonstrate the intracellular localization of the constructs, cells
were fixed and immunostained using an anti-TGN-46 antibody (fig. 10). TGN-46
is an integral membrane glycoprotein found in the trans Golgi network. Since
GFP is a cytosolic protein and is localized diffusely throughout the cell, it does
not co-localize with TGN-46. SPARC is secreted through the classical pathway
and therefore is processed in the Endoplasmic Reticulum and the Golgi Complex
(Mason et al., 1986). Both of the deletion mutant constructs are secreted (fig. 9C
and D), presumably through the same mechanism as wt-SPARC. Additionally,
SPARC and the deletion mutants co-localize with TGN-46 (fig. 10). This
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Figure 10. Intracellular processing of the constructs. Built confocal images
showing one clone expressing each of the constructs indicate the intracellular
processing of the constructs. The top panels showing GFP in each of the clones
indicate that the control GFP is localized diffusely throughout the cells, while
SPARC-GFP and the deletion mutants are localized perinuclear. The second set
of panels show expression of the trans Golgi marker TGN-46. The merged
images (bottom two rows of panels) indicate the constructs SPARC-GFP and
both deletion mutants, but not GFP co-localize with TGN-46, confirming their
localization to the Golgi complex. The bottom panels are zoomed images, to
better demonstrate the co-localization between the SPARC constructs and TGN46 and lack of co-localization between GFP and TGN-46. Images in the top three
sets of panels were captured at 60X. Zoomed images are 240X.
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perinuclear localization for all three constructs was expected since they are all
secreted, but this colocalization to the trans Golgi network supports proper
expression and processing for secretion of the deletion mutants.

Internalization of the Constructs by Naïve Cells
Studies have shown that SPARC is taken up by cells in culture (Gooden et
al., 1999; Kzhyshkowska et al., 2008; Zhang et al., 2009). Uptake is mediated by
the receptor stabilin-1 in macrophages (Kzhyshkowska et al., 2006; Zhang et al.,
2009) and occurs through the binding of SPARC to α5β1 integrin in adipose
stromal cells (Nie et al., 2008). The latter may be a mechanism for uptake of
SPARC in other cells, as integrins are widely expressed. SPARC is taken up by
U87MG cells (Rempel unpublished observations). We have found that the nonclonal U87MG cell line does not internalize SPARC uniformly and so for these
experiments we used a clone derived from U87MG, termed U87D8. This clone is
denoted as naïve because of its very low expression of endogenous SPARC and
because it does not express or secrete the SPARC-GFP-derived constructs. The
U87D8 cells were exposed to conditioned medium collected from clones
expressing each of the constructs. For visualization of uptake of the constructs
by confocal microscopy (fig. 11A), cells were exposed to conditioned medium for
three hours. Cells were then fixed and immunostained for EEA1, a protein
involved in early endosome trafficking. Since GFP is not secreted, there is none
in the conditioned medium to be taken up by cells as shown in figure 11A.
Fluorescence imaging demonstrates that SPARC-GFP and both deletion mutant
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Figure 11. Internalization of the constructs by naïve cells. U87D8 cells,
plated on FN-coated coverslips, exposed to conditioned medium from each of the
clones for 3 hr, were immunostained for the early endosomal marker EEA1. 60X
built confocal images are shown. (A) Top panels show the internalized
constructs. Note that GFP is not secreted and so there is no GFP in the
conditioned medium to be taken up by the cells. The second set of panels show
the EEA1 staining. The third set of panels consists of merged images showing
colocalization of SPARC-GFP and the two deletion mutants, indicating that they
are internalized into the endosomes. The bottom panels are zoomed-in images
(240X) of the merged images. (B) Western blot analysis of lysates (left panel)
collected from U87D8 after 6 hr exposure to conditioned media or SF OptiMEM
(denoted as SFM) shows that SPARC-GFP and both deletion mutants are
present in cell lysates of the naïve cells. The blot is labeled according to the
conditioned media to which the U87D8 cells were exposed. Actin indicates equal
loading of cell lysates. The level of SPARC-GFP or deletion mutant constructs
present in the conditioned media that the cells were exposed to is indicated in the
right panel. Molecular weights are indicated at the left of each blot.
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constructs were internalized by the U87D8 cells, as merged images of the green
fluorescent constructs and the EEA1 staining show co-localization, indicating
localization to the early endosome, which also points to proper folding of the
deletion mutants. The uptake of the EGF-like Module by the U87D8 cells
appeared less than SPARC and ∆Acidic, and so to verify this observation, we
performed Western blot analysis (fig. 11B) of lysates from U87D8 cells exposed
to conditioned medium. Lysates were collected at several time points up to 24 hr.
Very low levels of the constructs were seen taken up as early as within 10 min of
exposure to the conditioned medium (data not shown); however, uptake was best
observed by Western blot at 6 hr as shown in figure 11B or at later time points
(data not shown). The Western blots suggest that SPARC, ∆Acidic, and ∆EGF
are all internalized by the U87D8 cells; however, when comparing the levels of
the constructs in the conditioned medium to the levels of the constructs that were
internalized by the U87D8 cells, at the time points tested (3 hr, 6 hr, and 24 hr),
∆EGF was taken up to a lesser extent, and ∆Acidic was taken up to a greater
extent than SPARC, suggesting domain-specific interactions with a cell-surface
receptor. Interestingly, degradation products of the SPARC and ∆Acidic
constructs, which are presumed to be the GFP tag since it is approximately 29kDa and is detectable with the GFP antibody, were detectable as early as 3 hr.
However, there was no degradation product observed in the U87D8 cells
exposed to ∆EGF conditioned medium at any time point tested. Despite the lack
of a detectable degradation product, ∆EGF did not accumulate within the cells
any more than SPARC-GFP or ∆Acidic.
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∆Acidic Increases Cell Adhesion on Fibronectin
After determining that the constructs are not likely to be misfolded, we
next determined the effects of the deletions on cell adhesion. Adapting a method
described by Geise et al., (1994) clones were plated on increasing
concentrations of fibronectin with 10% BSA as a control. Adhesion was
determined 24 hr after plating (fig. 12). It should be noted that the results in figure
12 are shown as a percent of the absorbance of the control cells on each matrix
and that all cells were more adherent on all levels of FN than on 10% BSA. When
plated on 10% BSA, ∆Acidic cells were slightly more adherent than GFP control
cells, but were not significantly different from SPARC or ∆EGF. SPARC did not
affect adhesion when plated on the lower concentrations of FN compared to GFP
control cells, but SPARC increased adhesion when cells were plated on 100
µg/ml FN. Our results are in contrast to previous studies of SPARC in normal
cells, which indicated SPARC decreases adhesion (see Chapter I). However,
these previous studies used normal cells that were not plated on a matrix. Our
results may reflect a difference in tumor versus normal cells and/or matrixspecific effect of SPARC. Additionally, our results only slightly differ from
previous studies in our lab, which showed that SPARC expression did not alter
attachment on FN (Rempel et al., 2001) and differences observed may be an
effect of the different time points examined. Deletion of the Acidic Domain
increased cell adhesion on all levels of FN compared to GFP control cells and
∆EGF cells. These cells were also more adherent than SPARC-expressing cells
on the highest level of FN. Deletion of the EGF-like Module showed a trend for
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Figure 12. Deletion of the Acidic Domain increases cell adhesion. Adhesion
was measured 24 hr after plating. SPARC-expressing cells were more adherent
than GFP cells on the highest level of fibronectin (p = 0.0062). Deletion of the
Acidic Domain increased adhesion compared to control on all levels of FN and
on BSA (p ≤ 0.036). This deletion also increased adhesion on 100 µg/ml FN
compared to SPARC-expressing cells (p = 0.0095). Deletion of the EGF-like
Module decreased adhesion compared to control cells only on the lowest level of
FN (p = 0.03). These cells were not significantly different from SPARC on any
concentration of FN; however, they were significantly less adherent than ∆Acidic
on all concentrations of FN (p ≤ 0.03). * = Significantly different from GFP (p ≤
0.036), # = significantly greater than SPARC (p = 0.0095).
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decreasing adhesion. ∆EGF cells were less adherent than GFP cells on the
lowest level of FN, but were not significantly less adherent than SPARC cells on
any FN concentration. However, ∆EGF cells were less adherent than ∆Acidic
cells on all levels of FN.

Deletion of the Acidic Domain or EGF-like Module Reduces SPARC-Induced
Migration
We used a wound assay, which allowed us to measure the distance that
the cells migrated from the start of the wound. Figure 13A shows representative
images of one clone for each of the constructs (a line has been drawn to clarify
the start of migration). Figure 13B indicates the average distance migrated by
cells expressing each of the constructs. SPARC-expressing cells migrated a
significantly greater distance over 20 hr than the GFP-expressing cells, which is
consistent with our previous data (Golembieski et al., 2008). The SPARCexpressing cells also migrated significantly farther than the cells expressing
either of the two deletion mutant constructs. However, neither of the two deletion
mutants was able to reduce the SPARC-induced migration to control levels. The
deletion of the Acidic Domain did have a greater effect on SPARC-induced
migration than the deletion of the EGF-like Module, as cells expressing ∆Acidic
migrated significantly less than ∆EGF-expressing cells. To show that the cells
that are present in the wound area were a result of migration and not due to
increased proliferation, cell proliferation was measured over 48 hr. Approximately
twice the amount of time allowed for migration, was used in order to amplify
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Figure 13. SPARC-induced migration on fibronectin is reduced by the
deletion of the Acidic Domain or the EGF-like Module. (A) Representative
10X images of one clone expressing each of the constructs indicate cell
migration from the start of the wound after 20 hr. (B) Average distance migrated
for two clones expressing each of the constructs. SPARC significantly increased
migration over control. Migration was significantly reduced by deletion of the
Acidic Domain or the EGF-like Module when compared to SPARC-expressing
cells. However, both deletion mutants migrated significantly more than control
cells. * = Significantly less than SPARC (p ≤ 0.033), # = significantly greater than
GFP (p < 0.01). (C) Fold change in number of cells in SF OptiMEM at 24 and 48
hr relative to 0 hr, indicating that increased migration is not due to proliferation of
cells into the wound area.
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subtle changes in proliferation during the time allowed for migration. As shown in
figure 13C, there was no difference in proliferation among the eight clones over
this period of time.
To further confirm the effects of the deletions on cell migration, the
transwell assay was used to assess migration by the number of cells in SFOptiMEM that migrated through 8-µm pores. A chemoattractant of Opti-MEM
containing 10% serum is added to the lower chamber to induce migration through
the pores. Cells that migrated through to the bottom side of the transwell filters
within 2 hr were fixed, stained and imaged. Representative 10x images from
each of the four clones used in this assay are shown (fig. 14A). Figure 14B
indicates the average number of cells per field. As in the previous migration
assay, SPARC significantly increased cell migration compared to the GFPcontrol cells and both of the deletion mutants. However, in contrast to the wound
assay, both deletion mutants reduced SPARC-induced migration to levels similar
to the GFP-control cells. The differences observed between wound and transwell
migration assays indicated that the ECM may influence the activity of SPARC
and the deletion mutants.

∆Acidic and ∆EGF Reduce SPARC-Induced Activation of the p38
MAPK/HSP27 Pathway
We have previously demonstrated that p38 MAPK and HSP27 mediate
SPARC-induced migration (Golembieski et al., 2008). We used Western blot
analysis to determine the effects of the deletions on this signaling pathway (fig.
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Figure 14. ∆Acidic and ∆EGF reduce SPARC-induced migration through 8µm pores. (A) Representative 10X images of one clone expressing each of the
constructs after cells migrated through transwell filters with 8-µm pores for 2 hr.
(B) Average number of cells per field is shown. Expression of SPARC-GFP
increases cell migration compared to control cells. Deletion of the Acidic Domain
or the EGF-like Module reduces migration to control levels. * indicates
significantly less than SPARC p ≤ 0.001
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15). As in our previous study, SPARC expression increased p38 MAPK
phosphorylation (fig. 15A). The increased p38 MAPK activation is transient and
was only significantly different at 3 hr and when the cells were plated on the
highest level of FN tested (100 µg/ml), indicating that the SPARC-induced
activation of this pathway may be mediated through integrins. SPARC also
increased the expression of HSP27 versus GFP controls with a corresponding
increase in phosphorylation of HSP27 at all three serine residues (fig. 15Bi, ii, iii,
and v). Deletion of the Acidic domain or the EGF-like module showed a trend for
intermediate activation of p38 MAPK when compared to SPARC and GFP (fig.
15A). Deletion of the Acidic Domain resulted in a slight reduction in expression of
HSP27 compared to SPARC; however, phosphorylation of HSP27 was only
significantly less at Serine 82. HSP27 expression and phosphorylation was not
significantly different between ∆Acidic and GFP cells. The deletion of the EGFlike Module reduced expression of HSP27 compared to SPARC and ∆Acidic
cells; there was even a decrease in HSP27 expression compared to GFP cells.
Phosphorylation of HSP27 in the ∆EGF cells was significantly less than SPARC
and ∆Acidic cells, with a trend to decrease phosphorylation at all three sites
compared to GFP cells.
Because the level of expression and phosphorylation of HSP27 in the
∆EGF cells did not correlate with the level of migration in the wound assay and
the level of expression and phosphorylation of HSP27 in ∆Acidic cells did not
correlate with the very low level of migration in the transwell assay, we looked at
alternate signaling pathways that are known to be involved in migration to
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Figure 15. Deletion of the Acidic Domain or EGF-like Module reduces
SPARC-mediated signaling through the p38 MAPK/HSP27 signaling
pathway. (A i) Western blot analysis of expression and activation of p38 MAPK.
(A ii) Densitometric analysis indicates that SPARC increases phosphorylation of
p38 MAPK. The deletion mutants showed a trend for increased p38 activation,
but were not significantly different from GFP- or SPARC-expressing cells. (B i-iii)
Western blot analysis of HSP27 expression and phosphorylation at Serine 15 (i),
Serine 78 (ii), and Serine 82 (iii). (B iv) Western blot confirming equal expression
of the constructs. (B v) Densitometric analysis shows SPARC increases HSP27
expression and phosphorylation at all three Serines. Deletion of the Acidic
Domain reduces HSP27 expression and phosphorylation at Serine 82. Total or
phosphorylated HSP27 in ∆Acidic was not significantly different from control
cells. Deletion of the EGF-like Module decreased HSP27 expression and
phosphorylation to, or below control levels. * = Significantly less than SPARC (p
< 0.05), # = Significantly less than GFP (p < 0.016). Molecular weights are
indicated at the left of each blot.
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determine whether they could be preferentially activated by one or both of the
deletions. Others have shown that SPARC-induced migration is mediated in part
through the activation of FAK (Shi et al., 2007). We examined members of FAK
signaling pathways by Western blot and confocal imaging. We did not see
consistent effects on FAK activity by SPARC or either of the deletion mutants
under the conditions tested (data not shown). At the time points examined, there
was also no change in the intracellular localization of phosphorylated FAK in the
SPARC-expressing cells or in the deletion mutants compared to the GFP control
cells as determined by confocal imaging (data not shown). Western blot analysis
also indicated no change in the expression or activation of ERK or Myosin Light
Chain, which are downstream effectors of FAK, under the conditions tested (data
not shown).

SPARC-GFP and the Deletion Mutants Have No Effect on Glioma Cell
Invasion Through Matrigel
The decrease in migration by the deletion mutants compared to SPARCexpressing cells prompted us to investigate the effects of the deletions on cell
invasion using transwell filters coated with Matrigel. While Matrigel is composed
of different ECM proteins than was used in the wound assay and does not well
recapitulate the ECM present in the brain, it is a standard in vitro model to assess
invasion. We have previously reported that SPARC increases glioma invasion
through Matrigel (Golembieski et al., 2008). Cells plated on Matrigel-coated
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Figure 16. Deletion Mutants show a trend to increase invasion through
Matrigel. (A) Representative 20X images of cells 20 hr after plating on Matrigel.
(B) SPARC-GFP cells showed similar invasion to GFP-expressing cells. Both
∆EGF and ∆Acidic showed a trend for increased invasion. Results indicate the
average of two experiments, 6 images per well, 5 wells per experiment.
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transwell filters were allowed to invade for 20 hr. In contrast to our previous data,
SPARC expression did not increase invasion compared to control cells under the
conditions tested (fig. 16). The deletion mutants did, however, show a trend to
increase invasion compared to GFP- and SPARC-expressing cells (fig. 16).

SPARC-GFP and the Deletion Mutants Did Not Change MMP-2 Expression
or Activation
We demonstrated in figure 3 (Chapter III) that wt-SPARC (without the GFP
tag) increased expression and activation of MMP-2 when expressed in U87MG
cells. Gilles et al., (1998) showed that a peptide corresponding to a portion of the
Acidic Domain was involved in the SPARC-induced activation of MMP-2 in breast
cancer. Therefore, we were interested in the effects of the deletion mutants on
MMP-2 expression and activation. We performed gelatin zymography of cell
lysates and conditioned medium. SPARC-GFP did not increase MMP-2 activity
compared to GFP-expressing cells (Figure 17A and B). While this is in contrast to
data shown in Chapter III, it is consistent with other observations in our lab using
conditioned medium from clones expressing GFP and SPARC-GFP (Rempel
unpublished observations). It is apparent that a tag as large as GFP, or its
location at the C-terminus of SPARC, may interfere with some of the activity of
SPARC. The gelatin zymography was performed several times; however the
levels of MMP-2 in the lysates and the levels of active MMP-2 in the conditioned
medium were too low to quantitate by densitometry except in one experiment
each. There was no change in the levels of MMP-2 in the cell lysates between
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Figure 17. Deletion mutants show a trend to alter activation of MMP-2. (A)
The top panel indicates the levels of MMP-2 in cell lysates and indicates that
there are no detectable levels of active MMP-2 in the cell lysates. The lower
panel indicates the levels of latent and active MMP-2 in the conditioned medium.
The zymogram shown is the only zymogram where active MMP-2 was
measurable. (B) Quantitation of MMP-2 in the conditioned medium. Open bars
represent the latent MMP-2 and are the average of three experiments. The gray
bars indicate the levels of active MMP-2 in one zymogram (A).
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any of the clones (quantitation not shown). The levels of latent MMP-2 in the
conditioned medium in three experiments were quantifiable and are shown in
figure 17B, but there was no significant change in any of the clones. The active
MMP-2 in the conditioned medium shown in figure 17A was the only zymogram
in which we were able to quantitate the levels of active MMP-2 (shown in 17B).
∆Acidic shows a trend to decrease the levels of active MMP-2 and ∆EGF shows
a trend to increase active MMP-2; however, since only one zymogram had
measurable levels of active MMP-2 and it appears that the GFP tag may be
interfering with the activity of SPARC on MMP-2 regulation, additional
experiments must be done to reliably determine the effects of the deletion
mutants.
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Discussion
The evidence that different domains of SPARC may be involved in
different functions of SPARC prompted us to question whether the deletion of
specific domains would alter adhesion and/or signaling so as to reduce or
eliminate SPARC-induced glioma cell migration. SPARC is highly expressed in
gliomas and so the control, SPARC-GFP, and the two deletion mutant constructs
that we created were expressed in U87MG glioma cells, which express low levels
of SPARC. Deletion of the Acidic Domain or the EGF-like Module of SPARC did
not appear to significantly affect the processing and secretion of the protein, as
assessed by fluorescence (fig. 8) and confocal (fig. 10) imaging and Western blot
analyses (fig. 9). Both deletion mutants were localized to the trans Golgi network
(fig. 10) and were secreted (fig. 9), suggesting that they are glycosylated like wtSPARC. These data suggest that the constructs could be used to examine the
biological effects of the deletions on SPARC function in cell adhesion, migration,
invasion, and signaling.
Previous studies of SPARC peptides involving cell adhesion (discussed in
Chapter IV Introduction) prompted us to investigate the effects of the deletion
mutants on adhesion. Cell adhesion can be affected by the type and
concentration of ECM, expression levels of integrins, and expression of deadhesive proteins such as the matricellular proteins. To assess adhesion, we
examined β1 integrin expression and the affects of increasing levels of FN on
adhesion. FN is not a major component of the matrix in the brain except in blood
vessel basement membranes (Mahesparan et al., 2003). We chose to use FN for
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these studies because gliomas tend to migrate along blood vessels (Bellail et al.,
2004; Rempel and Mikkelsen, 2006). FN is required for the deposition of other
ECM proteins and for the proper organization of the ECM (Sottile and Hocking,
2002; Velling et al., 2002). FN is secreted by gliomas (Ohnishi et al., 1998) and
gliomas express FN receptors (Ohnishi et al., 1998; Rempel and Mikkelsen,
2006). Tumor cells may also induce host cells to produce ECM proteins including
FN (Mahesparan et al., 2003). In addition, the activity of SPARC is carried out, at
least in part, through integrins (Barker et al., 2005), prompting us to use a matrix
that engages integrins.
In this study, we demonstrated that SPARC increases adhesion on high
levels of FN compared to GFP control cells. Deletion of the Acidic Domain
increased adhesion compared to GFP- and ∆EGF-expressing cells on all levels
of FN and increased adhesion to a greater extent than SPARC on the highest
level of FN tested. Deletion of the EGF-like Module showed a trend for
decreased adhesion on all concentrations of FN compared to SPARC and GFP
cells and were significantly less adherent than GFP cells on the lowest level of
FN. The data suggest that on FN, the binding of SPARC with FN and with β1
integrin may act to reinforce the integrin binding to the matrix; however, the
Acidic Domain has de-adhesive properties (Lane and Sage, 1990; Murphy-Ullrich
et al., 1995). Therefore, the balance between these two characteristics causes
the cells to be similarly adherent to the GFP-expressing cells (fig. 12), but the
effects of the Acidic Domain can be overpowered by increasing the concentration
of FN, resulting in increased adhesion. This is also observed by the deletion of
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the EGF-like Module. In this construct the Acidic Domain is positioned closer to
the β1 integrin binding site on SPARC and so, at least at lower levels of FN, it
may have a greater ability to disrupt the interaction between β1 and FN, resulting
in decreased adhesion. As with SPARC, this effect is overcome by increasing the
concentration of FN. Deletion of the Acidic Domain results in increased adhesion
due to the loss of the de-adhesive domain. The Acidic Domain is also involved in
the suppressive effect of SPARC on FN production (Lane et al., 1992), and so
deletion of this domain would result in greater deposition of FN compared to
SPARC and ∆EGF, resulting in increased adhesion. Additionally, a construct
lacking the Acidic Domain showed increased affinity for Collagen IV (Maurer et
al., 1995). Our data suggest that ∆Acidic may also have increased affinity for FN,
causing these cells to be more adherent than GFP-expressing cells.
Studies have shown that SPARC modulates adhesion through the
decreased cell surface expression of β1 and αv integrins (Said et al., 2007), both
of which can participate in FN binding. We found no change in the expression of
β1 integrin in whole cell lysates in our cells (data not shown); however, levels of
αv and the localization of integrins were not investigated. The mechanism for the
SPARC-mediated decrease in integrin expression is not known; however, if the
Acidic Domain is involved, then deleting the Acidic Domain may result in an
increase in integrin αv, which could result in increased attachment to FN
compared to SPARC-expressing cells. However, it is more likely that the
deletions affect adhesion through changes in the interaction between SPARC
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and β1 integrin. This hypothesis is further supported by the differences observed
in uptake of the deletion mutants by naïve cells.
In adipose stromal cells, SPARC is internalized by binding to α5β1 integrin
(Nie et al., 2008). While the mechanism for uptake of SPARC in glioma cells is
unknown, α5β1 integrin is a candidate receptor as U87MG cells express α5β1
(Maglott et al., 2006). Uptake of SPARC and the deletion mutants may be
through β1 integrin since both deletion mutants have the region of SPARC that
binds to β1 integrin (Weaver et al., 2008); however, uptake of ∆EGF was
reduced, while ∆Acidic was enhanced compared to SPARC (fig. 11). The EGFlike Module is in the same domain as the β1 integrin binding site and is in close
proximity to it in the secondary structure (fig.1). The data suggest that while the
EGF-like Module is not required for binding and internalization of SPARC, it may
increase the affinity of SPARC for β1 integrin. This agrees with an observation by
Yost and Sage (1993), who demonstrated that a peptide mimicking the EGF-like
Module was a more potent competitor for cell surface binding than wt-SPARC.
Therefore, the deletion of the EGF-like Module would likely decrease binding to a
cell surface receptor such as β1 integrin. Deletion of the Acidic Domain, which
places the EGF-like Module at the N-terminus of the mature protein (fig. 7),
resulted in enhanced uptake compared to SPARC, which further suggests that
the EGF-like Module promotes the binding of SPARC to β1 integrin.
While only ∆Acidic increased adhesion, both deletion mutants decreased
migration when compared with wt-SPARC-GFP-expressing cells. The extent of
the effects on migration was dependent on the assay used to measure migration.
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In the wound assay, cells were plated on FN and migration was along a flat
surface, without spatial constraints (fig. 13A). In the transwell assay, there was
no matrix added to the inserts, but the cells had to move through the pores in the
filters (fig. 14A), which would provide spatial constraint. The deletion mutants
reduced migration compared to SPARC; however the cells migrated significantly
more than the control cells in the wound assay (fig. 13), but similarly to control
cells in the transwell assay (fig. 14). The differences between the two assays
indicate that the actions of the deletion mutants are dependent on the matrix or
that they are involved in SPARC signaling to Myosin II. Myosin II is required for
glioma migration through the pores of transwell filters (Beadle et al., 2008) and
both deletions reduced migration to control levels in the transwell migration
assay. While we did not see changes in phosphorylated Myosin Light Chain by
Western blot under the conditions tested, others have shown that SPARC
activates Myosin though ILK-mediated activation of Myosin Light Chain or
inhibition of Myosin Light Chain Phosphatase, which is an inhibitor of Myosin
Light Chain (Barker et al., 2005). However, we have previously demonstrated
that SPARC induced migration in the wound assay as well as invasion through
Matrigel coated transwell filters is inhibited by HSP27 siRNA (Golembieski et al.,
2008), indicating that SPARC-induced migration, whether on a surface or through
a pore, is mediated by HSP27. Additionally, in the invasion assay, which also
uses the same transwell filters as in the transwell migration assay, both deletion
mutants showed a trend to increase invasion compared to SPARC-GFPexpressing cells, indicating that the mutations do not compromise the Myosin-
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mediated migration that cells employ when they are under spatial constraint.
Based on these results and the changes in binding of the constructs to β1
integrin discussed above, it is more likely that the differences observed between
the two assays are due to the presence or absence of FN.
We have previously shown that SPARC-induced migration is mediated
through the increased expression and phosphorylation of HSP27. In cells
expressing ∆Acidic, the decreased migration (figs. 13 and 14) correlated with
decreased expression of HSP27 and phosphorylation at serine 82 (fig. 15B)
compared to SPARC-expressing cells. The ∆Acidic cells were not significantly
different from the GFP cells in the level of HSP27 expression and
phosphorylation (fig. 15), which correlates well with the similar level of migration
as measured by the transwell assay (fig. 14). Additionally, there was a trend for
an increase in phosphorylation of HSP27 at serines 78 and 82 in ∆Acidic
compared to GFP cells, which may explain the slight increase in migration in the
wound assay (fig. 13). Considering the evidence that this construct is able to bind
to integrins, the data suggest that the Acidic Domain is important in the activation
of SPARC-induced signaling through the p38 MAPK/HSP27 pathway.
Despite the low levels of HSP27, clones expressing ∆EGF migrated a
greater distance than the ∆Acidic and GFP cells in the wound assay (fig. 13).
Deletion of the EGF-like Module resulted in a reduction in the expression of
HSP27 to less than GFP-control levels; however, the levels of phosphorylated
HSP27 in the ∆EGF cells were not significantly less than GFP cells. The relative
levels of phosphorylated and unphosphorylated HSP27 may be critical in the
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function of this protein. Unphosphorylated HSP27 acts as an actin capping
protein, preventing polymerization and migration, while phosphorylated HSP27
stabilizes the actin filaments at the base of the lamellipodia, preventing
depolymerization and facilitating migration (Pichon et al., 2004). The high degree
of phosphorylation relative to the low level of total HSP27 present in the ∆EGF
cells may be able to promote migration due to a low availability of
unphosphorylated HSP27 to contribute to actin capping. The mechanism by
which SPARC upregulates HSP27 is unknown. It is clear from our studies that
the EGF-like Module is essential in SPARC-mediated upregulation of HSP27.
Further studies of this construct may yield insight into the SPARC – HSP27
relationship.
In contrast to results shown in Chapter III, there was no change in MMP-2
expression or activation in control versus SPARC expressing cells (fig. 17). An
independent investigation with other U87MG-derived clones expressing GFP and
SPARC-GFP fusion constructs confirmed that these results may be due to the
presence of the GFP-tag (Rempel, unpublished observations). However, the
deletion mutants did affect MMP-2 activation. While only one zymogram had
measurable levels of active MMP-2 in the conditioned medium, this preliminary
data suggest that the Acidic Domain may promote the activation of MMP-2.
When the Acidic Domain is deleted, MMP-2 activation decreased compared to
GFP- and SPARC-expressing cells, which is consistent with data reported by
Gilles et al., (1998). When the EGF-like Module was deleted, MMP-2 activation
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increased; however, additional studies must be done to determine the
consistency and significance of these results.
There was also no change in invasion through Matrigel between SPARC
and GFP cells (fig. 16). This is consistent with the level of MMP-2 activity, but is
not consistent with our previous results (Golembieski et al., 2008), in which the
expression of SPARC-GFP increased invasion compared to GFP-expressing
cells. While this may be due to clonal variability, as the transfections were done
at a different time, using different methods and into a different passage number
of U87MG cells, it is more likely due to differences in Matrigel preparations
(Hughes et al., 2010).
Based on our results, we propose the following model (fig. 18). SPARC
binds FN through the E-C Domain and binds β1 integrin through the C-terminal
region of the FS Domain. Binding to β1 is enhanced by the EGF-like Module. The
interaction of these SPARC domains with β1 and FN supports integrin – FN
binding; however, the Acidic Domain interferes with the binding of the integrin
with FN. Therefore, in this complex, there is a balance between the de-adhesive
Acidic Domain and the FS and E-C Domains which are helping to tether the
integrin to the matrix. However, the effects of the Acidic Domain can be
overcome at higher levels of FN, increasing adhesion. The Acidic Domain is also
involved in the activation of ILK and downstream signaling pathways, which may
also result in the induction of MMP-2 and a decrease in FN production.
Therefore, deletion of the Acidic Domain results in a construct that can bind to
the integrin very well, but does not disrupt the adhesion complex and cannot
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Figure 18. Working model. The constructs are illustrated by the sum of the
domains/module; AD = Acidic Domain (black), EGF = EGF-like Module (yellow),
FS = Follistatin-like Domain (red), EC = Extracellular Calcium Binding Domain
(blue) and are illustrated without the GFP-tag for simplicity. Note that the size of
the arrows indicates relative level of activation or change. (A-C) When cells are
plated on FN, (A) WT-SPARC binds to FN and β1 integrin. The interaction with
β1 integrin activates p38 MAPK and HSP27, most likely through ILK, resulting in
cell migration. (B) Deletion of the Acidic Domain results in a construct with
increased ability to bind FN and integrins, which results in increased cell
adhesion, but without the Acidic Domain it has less ability to activate ILK and
downstream signaling pathways. (C) ∆EGF binds to FN, which localizes the
construct near integrins, but it has reduced capacity to bind the integrins. The
presence of the Acidic Domain reduces adhesion when FN is low and also can
induce signaling; however, since HSP27 is reduced, cells expressing this
deletion have reduced migration compared to SPARC. (D) When FN is not
present, SPARC and ∆Acidic can still bind to β1 integrin, but only SPARC can
activate signaling pathways that induce migration. Without FN, ∆EGF is not
localized to the integrins and so does not bind and migration is reduced to control
levels.
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activate ILK and downstream signaling pathways such as p38 MAPK/HSP27 as
effectively as SPARC. This construct also does not suppress FN production,
which contributes to the observed increase in adhesion. The decreased p38
MAPK/HSP27 signaling combined with the increased adhesion, results in
decreased migration. Deletion of the EGF-like Module yields a construct that
does not bind to the integrin efficiently; however, because the construct binds
FN, it can be brought into close proximity with integrins. The small amount that
does bind has an enhanced ability to disrupt the adhesion complex because
when the EGF-like Module is deleted, the de-adhesive Acidic Domain is placed
closer to the β1 binding site on SPARC. However this deadhesive property is
eliminated by increasing the concentration of FN. The reduced ability for this
construct to bind to the integrin results in loss of p38 MAPK/HSP27 signaling and
decreased migration.
In the absence of matrix, as in the transwell assay, SPARC is still able to
bind to integrins and induce signaling for migration. ∆Acidic can also bind to
integrins, but does not induce the signaling required for migration, resulting in
reduced migration compared to SPARC. The binding of ∆EGF is even further
reduced in the absence of FN because there is no matrix for the construct to bind
and therefore ∆EGF is not recruited to the integrins, resulting in reduced
migration.
Studies have implicated SPARC or SPARC peptides as a therapy for
cancers in which SPARC proves a positive prognostic marker (Atorrasagasti et
al., 2010; Chlenski and Cohn, 2010). Expression of the ∆Acidic construct

90
increased glioma cell adhesion and reduced SPARC-induced migration and
signaling through HSP27, though the effects on invasion are unclear. While some
of the effects of this deletion mutant must be examined in more detail, the
∆Acidic construct may prove effective in the treatment of cancers where SPARC
is associated with good or poor prognosis. Others have shown that peptides that
mimic all or part of the EGF-like Module were effective in blocking angiogenesis
associated with neuroblastoma (Chlenski et al., 2004; Chlenski and Cohn,
2010). ∆Acidic has an intact EGF-like Module and the absence of the Acidic
Domain places the EGF-like Module at the N-terminus of the protein, resulting in
a protein that can compete for SPARC binding with limited induction of signaling.
Therefore this construct may retain this anti-angiogenic activity. Further analysis
of these deletion mutants will give more insight into the effects on SPARCexpressing tumors.
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CHAPTER V FUTURE DIRECTIONS
To completely appreciate the effects of these deletions on SPARC activity,
it will be necessary to create the constructs without the GFP tag. It may also be
beneficial to express the constructs in cells that do not express SPARC. This
would be possible using SPARC siRNA as the 3’ untranslated region that the
siRNA binds is not present in our constructs; however the effects of the
transfection reagents may add another level of complexity to the interpreting the
results. Additional studies such as cross-linking and/or co-immunoprecipitation of
the constructs with β1 integrin will give better insight into the interactions of
SPARC and the integrin. In addition, since current in vitro models do not
adequately recapitulate the brain parenchyma, studying these deletion mutants in
vivo, in a rat xenograft model as previously described by our lab (Schultz et al.,
2002, Thomas et al., 2010), would provide information about how the deletions
affect glioma invasion in the brain.
Since deletion of the Acidic Domain causes increased adhesion,
decreased migration, and potentially reduced MMP-2 activity, compared to
SPARC, it would be beneficial to examine whether this deletion mutant can
compete for binding with wt-SPARC. If it does indeed compete for binding, and
can reduce the invasive capacity of the tumor cells, this deletion mutant could
prove to be a valuable therapy in tumor expressing high levels of SPARC.
Further studies of the ∆EGF clones may also provide information on the
mechanism by which SPARC upregulates HSP27. Since HSP27 is also involved
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in survival pathways, information about its regulation by SPARC may also yield a
potential target for therapy in SPARC-expressing tumors.
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APPENDIX
PREVIOUSLY PUBLISHED DATA

The image shown in figure 1 was adapted from a figure in the following
manuscript:
Bradshaw AD and Sage EH (2001) SPARC, a matricellular protein that functions
in cellular differentiation and tissue response to injury. J Clin Invest 107:10491054.

The content contained in Chapter III including figures and the methods
pertaining to those experiments were previously published in the following
manuscript:
McClung HM, Thomas SL, Osenkowski P, Toth M, Menon P, Raz A, Fridman R
and Rempel SA (2007) SPARC upregulates MT1-MMP expression, MMP-2
activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells.
Neurosci Lett 419:172-177.

All previously published content was republished in this dissertation with
permission.
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We have previously shown that Secreted Protein Acidic and Rich in
Cysteine (SPARC) is upregulated in all astrocytoma grades and increases tumor
cell migration and invasion. It is thought that different domains within the protein
may regulate SPARC functions, suggesting domain-specific targeting to inhibit
invasion. To enhance our understanding of SPARC-mediated invasion, we first
confirm, at the protein level, our previous cDNA array results, that SPARC
increases expression of the matrix metalloproteases (MMPs) MT1-MMP and
MMP-2. We also demonstrate that SPARC increases MMP-2 activation and the
secretion and processing of galectin-3, a known target of MMPs. To investigate
the roles of specific domains, we used a SPARC-GFP fusion protein and deletion
mutant constructs of SPARC-GFP with deletions of either the Acidic Domain
(∆Acidic) or EGF-like Module (∆EGF). We confirm our previous findings that
SPARC-GFP increased migration and activation of p38 MAPK and HSP27
signaling compared to GFP control cells. ∆Acidic increases cell adhesion and
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reduces SPARC-induced migration and p38 MAPK/HSP27 signaling. ∆EGF
decreases SPARC-induced migration and dramatically decreases the expression
and phosphorylation of HSP27. The extent to which the deletions reduced
migration was dependent upon the presence of extracellular matrix. Preliminary
data also suggest that the deletions affect invasion and MMP-2 activation. In
conclusion, both regions of interest regulate SPARC-induced migration and
signaling though the p38 MAPK/HSP27 signaling pathway. Importantly, their
impact on migration is influenced by the presence or absence of extracellular
matrix. This and future studies of the deletion mutants will provide valuable
insight into new strategies that effectively target invasion in SPARC-expressing
tumors.
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